[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1146
1. Forgue-Lafitte ME, Fabiani B, Levy PP, Maurin N, Fléjou JF, Bara J: Abnormal expression of M1/MUC5AC mucin in distal colon of patients with diverticulitis, ulcerative colitis and cancer. Int J Cancer; 2007 Oct 1;121(7):1543-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal expression of M1/MUC5AC mucin in distal colon of patients with diverticulitis, ulcerative colitis and cancer.
  • The abnormal expression of gastric M1/MUC5AC mucin in precancerous lesions and colon cancer evidenced by immunohistochemistry led us to check for its presence in the mucus obtained directly from patients undergoing surgery for cancerous (adenocarcinoma) or inflammatory (diverticulitis or ulcerative colitis) diseases.
  • In parallel, the authors quantified aberrant crypt foci (ACF) and their immunolabelling by M1/MUC5AC in mucosae of cancer and diverticulitis patients.
  • Immuno-Radio-Metric Assay of M1/MUC5AC mucin developed by the authors was used to detect M1/MUC5AC mucin in the colonic mucus scraped from surgical specimens.
  • M1/MUC5AC mucin was detected in the mucus of 51/69 (74%) patients with colon adenocarcinoma, versus 7/27 (26%) patients with diverticulitis (threshold: 30 units of M1 mucin per mg protein, area under ROC curve: 0.80).
  • M1/MUC5AC was present in significantly (p < 0.001) larger amounts in the mucus of cancer versus diverticulitis patients.
  • Patients with cancer exhibited 3 fold more ACF than those with diverticulitis, but no significant difference was observed in the mean size and M1/MUC5AC expression pattern of ACF between these two groups.
  • Testing of M1/MUC5AC can enhance the detection of precancerous lesions and colon cancer.
  • [MeSH-major] Colitis, Ulcerative / pathology. Colon / pathology. Colonic Neoplasms / pathology. Diverticulitis / pathology. Mucins / biosynthesis


2. Neunlist M, Aubert P, Bonnaud S, Van Landeghem L, Coron E, Wedel T, Naveilhan P, Ruhl A, Lardeux B, Savidge T, Paris F, Galmiche JP: Enteric glia inhibit intestinal epithelial cell proliferation partly through a TGF-beta1-dependent pathway. Am J Physiol Gastrointest Liver Physiol; 2007 Jan;292(1):G231-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, mucosal glial network (assessed by immunohistochemical detection of S-100beta) is altered in colon adenocarcinoma compared with control tissue.
  • Functional alterations in EGCs may therefore modify intestinal barrier functions and be involved in pathologies such as cancer or inflammatory bowel diseases.
  • [MeSH-major] Adenocarcinoma / pathology. Intestinal Mucosa / cytology. Intestinal Mucosa / innervation. Intestinal Neoplasms / pathology. Intestine, Small / cytology. Neuroglia / cytology. Transforming Growth Factor beta1 / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16423922.001).
  • [ISSN] 0193-1857
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta1
  •  go-up   go-down


3. Wilde BK, Senger JL, Kanthan R: Gastrointestinal schwannoma: an unusual colonic lesion mimicking adenocarcinoma. Can J Gastroenterol; 2010 Apr;24(4):233-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal schwannoma: an unusual colonic lesion mimicking adenocarcinoma.
  • Gastrointestinal schwannoma is a rare, benign pathological entity that can mimic colonic adenocarcinoma and cause diagnostic dilemmas for treatment.
  • A case of a 68-year-old woman with colonic adenocarcinoma who was discovered to have an incidental synchronous bowel lesion that proved to be a gastrointestinal schwannoma and not a synchronous adenocarcinoma is described.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colonic Neoplasms / diagnosis. Neurilemmoma / diagnosis

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2001;31(9):833-8 [11686568.001]
  • [Cites] Dis Esophagus. 2009;22(4):E6-E10 [19473209.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):660-7 [12949711.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1361-71 [13679444.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1992 Apr;73(4):469-71 [1374171.001]
  • [Cites] Am J Surg Pathol. 1995 Jan;19(1):59-70 [7802139.001]
  • [Cites] J Gastroenterol. 1998 Dec;33(6):872-5 [9853563.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):431-6 [10199472.001]
  • [Cites] World J Gastroenterol. 2005 Aug 28;11(32):5079-81 [16124072.001]
  • [Cites] Histopathology. 2006 Apr;48(5):536-45 [16623779.001]
  • [Cites] Adv Anat Pathol. 2007 May;14(3):178-88 [17452814.001]
  • [Cites] Virchows Arch. 2007 Sep;451(3):717-20 [17622556.001]
  • [Cites] World J Gastroenterol. 2007 Nov 7;13(41):5521-4 [17907300.001]
  • [Cites] Ann Diagn Pathol. 2008 Apr;12(2):146-52 [18325478.001]
  • [Cites] Clin Radiol. 2008 May;63(5):536-42 [18374717.001]
  • [Cites] Yonsei Med J. 2008 Dec 31;49(6):1052-4 [19108033.001]
  • [Cites] APMIS. 2009 Feb;117(2):73-86 [19239429.001]
  • [Cites] World J Gastroenterol. 2009 May 14;15(18):2287-9 [19437573.001]
  • [Cites] Science. 2003 Jan 31;299(5607):708-10 [12522257.001]
  • (PMID = 20431810.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2864617
  •  go-up   go-down


Advertisement
4. Chaleoykitti B: Preoperative diagnosis of urinary bladder involvement in adenocarcinoma of colon and rectum. J Med Assoc Thai; 2005 Dec;88(12):1816-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative diagnosis of urinary bladder involvement in adenocarcinoma of colon and rectum.
  • OBJECTIVE: Objective of the study was to compare urinary symptoms, urinalysis, computed tomography, intravenous pyelography, ultrasonography between colorectal adenocarcinoma with urinary bladder involvement and without urinary bladder involvement.
  • MATERIAL AND METHOD: Patients with adenocarcinoma of the colon and rectum who had the first operation between January 1999 and October 2004 were included in the present study.
  • CONCLUSION: History of urinary symptoms, urinalysis, computed tomography should be routinely performed in patients with adenocarcinoma of the sigmoid and rectum to detect urinary bladder involvement and to inform modes of urinary tract diversion to patients before surgery.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Rectal Neoplasms / pathology. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518979.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


5. Saovapakhiran A, D'Emanuele A, Attwood D, Penny J: Surface modification of PAMAM dendrimers modulates the mechanism of cellular internalization. Bioconjug Chem; 2009 Apr;20(4):693-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to investigate the influence of dendrimer surface properties on cellular internalization and intracellular trafficking in the human colon adenocarcinoma HT-29 cell line.

  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19271737.001).
  • [ISSN] 1520-4812
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dendrimers; 0 / PAMAM Starburst; 0 / Polyamines; 9Y8NXQ24VQ / Propranolol; I223NX31W9 / Fluorescein-5-isothiocyanate
  •  go-up   go-down


6. Rojas A, Meherem S, Kim YH, Washington MK, Willis JE, Markowitz SD, Grady WM: The aberrant methylation of TSP1 suppresses TGF-beta1 activation in colorectal cancer. Int J Cancer; 2008 Jul 1;123(1):14-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The aberrant methylation of TSP1 suppresses TGF-beta1 activation in colorectal cancer.
  • Colorectal cancer arises from the progressive accumulation of mutations and epigenetic alterations in colon epithelial cells.
  • Such alterations often deregulate signaling pathways that affect the formation of colon cancer, such as the Wnt, RAS-MAPK and TGF-beta pathways.
  • The tumor promoting effects of mutations in genes, such as APC, have been demonstrated in cancer cell lines and in mouse models of intestinal cancer; however, the biological effects of most epigenetic events identified in colorectal cancer remain unknown.
  • We found methylated TSP1 occurs in colon cancer cell lines (33%), colon adenomas (14%) and colon adenocarcinomas (21%).
  • Our results demonstrate that the aberrant methylation of TSP1 has biological consequences and provide evidence that the aberrant methylation of TSP1 is a novel epigenetic mechanism for suppressing TGF-beta signaling in colorectal cancer.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):793-800 [17311026.001]
  • [Cites] Nat Med. 1996 Feb;2(2):169-74 [8574961.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):157-8 [17200673.001]
  • [Cites] Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):159-68 [10708963.001]
  • [Cites] Cell. 1996 Jun 28;85(7):947-50 [8674122.001]
  • [Cites] Cell. 1998 Jun 26;93(7):1159-70 [9657149.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3101-4 [9679977.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):320-4 [9927040.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):798-802 [10029065.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2307-12 [10344734.001]
  • [Cites] Oncogene. 1999 May 27;18(21):3284-9 [10359534.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):1029-37 [16234815.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Nov;131(11):733-40 [16075282.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40 [16289860.001]
  • [Cites] Nat Genet. 2006 Feb;38(2):149-53 [16444255.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):107-16 [16491070.001]
  • [Cites] Biochim Biophys Acta. 2006 Apr;1765(2):178-88 [16406676.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4566-73 [16651406.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Aug;45(8):781-9 [16708352.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3713-5 [16778097.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9837-44 [17047044.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):59-69 [10708953.001]
  • [Cites] Cancer Lett. 2007 Mar 18;247(2):283-92 [16828225.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):16-7 [10973239.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):854-65 [10982779.001]
  • [Cites] Curr Top Microbiol Immunol. 2001;254:145-64 [11190572.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):999-1009 [11309351.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):117-29 [11586292.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(5):1369-78 [11839804.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4562-7 [11904375.001]
  • [Cites] Cancer Cell. 2002 May;1(4):299-305 [12086841.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8412-7 [12829793.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6299-310 [14559817.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):417-22 [15034581.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3474-80 [14990990.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4687-92 [15256431.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):846-53 [15386372.001]
  • [Cites] J Cell Biol. 1991 Aug;114(4):827-39 [1869589.001]
  • [Cites] J Clin Invest. 1994 Mar;93(3):1005-13 [8132740.001]
  • [Cites] Science. 1994 Sep 9;265(5178):1582-4 [7521539.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):5101-5 [7585558.001]
  • [Cites] Cell Cycle. 2007 May 2;6(9):1040-3 [17457052.001]
  • (PMID = 18425817.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA115513-01A2; United States / NCI NIH HHS / CA / R01 CA115513; United States / NCI NIH HHS / CA / R01 CA115513-01A2
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / SMAD2 protein, human; 0 / Smad2 Protein; 0 / Thrombospondin 1; 0 / Transforming Growth Factor beta1
  • [Other-IDs] NLM/ NIHMS156274; NLM/ PMC2777657
  •  go-up   go-down


7. Baek JO, Lee HY, Lee JR, Roh JY: Acrokeratosis Paraneoplastica with Adenocarcinoma of the Colon Treated with Topical Tretinoin. Ann Dermatol; 2008 Dec;20(4):216-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acrokeratosis Paraneoplastica with Adenocarcinoma of the Colon Treated with Topical Tretinoin.
  • Ten months before she had been diagnosed with adenocarcinoma of the colon and undergone a left hemicolectomy.
  • We report a case of acrokeratosis paraneoplastica associated with colon cancer which persisted after removal of the primary cancer, but resolved with topical tretinoin treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27303196.001).
  • [ISSN] 1013-9087
  • [Journal-full-title] Annals of dermatology
  • [ISO-abbreviation] Ann Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC4903983
  • [Keywords] NOTNLM ; Acrokeratosis paraneoplastica / Bazex syndrome / Colon cancer / Tretinoin
  •  go-up   go-down


8. Hsu SC, Lu JH, Kuo CL, Yang JS, Lin MW, Chen GW, Su CC, Lu HF, Chung JG: Crude extracts of Solanum lyratum induced cytotoxicity and apoptosis in a human colon adenocarcinoma cell line (colo 205). Anticancer Res; 2008 Mar-Apr;28(2A):1045-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crude extracts of Solanum lyratum induced cytotoxicity and apoptosis in a human colon adenocarcinoma cell line (colo 205).
  • The effects of the crude extract of Solanum lyratum (SLE) on human colon cancer colo 205 cells were investigated.
  • The findings show that SLE might be used as a colon cancer therapeutic agent in the future.
  • [MeSH-major] Adenocarcinoma / drug therapy. Colonic Neoplasms / drug therapy. Plant Extracts / pharmacology. Solanum / chemistry

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507053.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Reactive Oxygen Species
  •  go-up   go-down


9. Bishnupuri KS, Luo Q, Murmu N, Houchen CW, Anant S, Dieckgraefe BK: Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas. Gastroenterology; 2006 Jan;130(1):137-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas.
  • METHODS: To determine the signaling pathway(s) responsive to Reg IV, we examined the effects of purified recombinant human Reg IV (rhR4) on HCT116 and HT29 colon adenocarcinoma cells.
  • Disruption of Reg signaling may have utility as a therapeutic intervention for human gastrointestinal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / physiopathology. Colonic Neoplasms / genetics. Colonic Neoplasms / physiopathology. Lectins, C-Type / physiology


10. Lo KL, Khalil AT, Kuo YH, Shen YC: Sinuladiterpenes A-F, new cembrane diterpenes from Sinularia flexibilis. Chem Biodivers; 2009 Dec;6(12):2227-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Compound 2 exhibited significant in vitro cytotoxic activity against human colon adenocarcinoma (WiDr) cell line.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20020460.001).
  • [ISSN] 1612-1880
  • [Journal-full-title] Chemistry & biodiversity
  • [ISO-abbreviation] Chem. Biodivers.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diterpenes
  •  go-up   go-down


11. Ahmadnia H, Molaei M: Concomitant presence of renal cell carcinoma and adenocarcinoma of the colon. Saudi J Kidney Dis Transpl; 2009 Nov;20(6):1081-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant presence of renal cell carcinoma and adenocarcinoma of the colon.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Renal Cell / pathology. Colonic Neoplasms / pathology. Kidney Neoplasms / pathology. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861877.001).
  • [ISSN] 1319-2442
  • [Journal-full-title] Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • [ISO-abbreviation] Saudi J Kidney Dis Transpl
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


12. Reddy BS, Wang CX, Kong AN, Khor TO, Zheng X, Steele VE, Kopelovich L, Rao CV: Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res; 2006 Apr 15;66(8):4542-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats.
  • Preclinical and clinical studies have provided evidence that aspirin, celecoxib, (cyclooxygenase-2 inhibitor), and statins (3-hydroxy-3-methylglutaryl CoA reductase inhibitors) inhibit colon carcinogenesis.
  • We assessed the efficacy of atorvastatin (lipitor), celecoxib, and aspirin, given individually at high dose levels and in combination at lower doses against azoxymethane-induced colon carcinogenesis, in male F 344 rats.
  • Rats were killed 42 weeks later, and colon tumors were processed histopathologically and analyzed for cell proliferation and apoptosis immunohistochemically.
  • Administration of these agents individually and in combination significantly suppressed the incidence and multiplicity of colon adenocarcinomas.
  • Low doses of these agents in combination inhibited colon carcinogenesis more effectively than when they were given individually at higher doses.
  • Inhibition of colon carcinogenesis by these agents is associated with the inhibition of cell proliferation and increase in apoptosis in colon tumors.
  • These observations are of clinical significance because this can pave the way for the use of combinations of these agents in small doses against colon cancer.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Aspirin / pharmacology. Colonic Neoplasms / prevention & control. Heptanoic Acids / pharmacology. Pyrazoles / pharmacology. Pyrroles / pharmacology. Sulfonamides / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618783.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01-CA-37663; United States / NCI NIH HHS / CA / 1R01-CA-94962; United States / NCI NIH HHS / CA / CA-17613; United States / NCI NIH HHS / CN / N01-CN-43308
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Carcinogens; 0 / Heptanoic Acids; 0 / Pyrazoles; 0 / Pyrroles; 0 / Sulfonamides; 48A5M73Z4Q / Atorvastatin Calcium; JCX84Q7J1L / Celecoxib; MO0N1J0SEN / Azoxymethane; R16CO5Y76E / Aspirin
  •  go-up   go-down


13. Suresh D, Balakrishna MS, Rathinasamy K, Panda D, Mague JT: Large-bite bis(phosphite) ligand containing mesocyclic thioether moieties: synthesis, reactivity, group 11 (Cu(I), Au(I)) metal complexes and anticancer activity studies on a human cervical cancer (HeLa) cell line. Dalton Trans; 2008 May 7;(17):2285-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large-bite bis(phosphite) ligand containing mesocyclic thioether moieties: synthesis, reactivity, group 11 (Cu(I), Au(I)) metal complexes and anticancer activity studies on a human cervical cancer (HeLa) cell line.
  • The compounds were tested for their cytotoxic activity on the human cervical cancer (HeLa) cell line.
  • These agents also induced apoptotic cell death in cancer cells.
  • Evidence presented in this study indicated that the compounds and activate the tumor suppressor protein p53 in the colon adenocarcinoma (HCT-116) cell line.

  • Genetic Alliance. consumer health - Cervical cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GOLD COMPOUNDS .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414753.001).
  • [ISSN] 1477-9226
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Gold Compounds; 0 / Ligands; 0 / Organogold Compounds; 0 / Organometallic Compounds; 0 / Phosphites; 0 / Sulfides; 0 / Tumor Suppressor Protein p53; 789U1901C5 / Copper
  •  go-up   go-down


14. Emmenegger U, Morton GC, Francia G, Shaked Y, Franco M, Weinerman A, Man S, Kerbel RS: Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res; 2006 Feb 1;66(3):1664-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recent clinical successes of antiangiogenic drug-based therapies have also served to highlight the problem of acquired resistance because, similar to other types of cancer therapy, tumors that initially respond eventually stop doing so.
  • With this in mind, we measured the oxygenation of PC-3 human prostate cancer xenografts subjected to chronic low-dose metronomic (LDM) antiangiogenic chemotherapy using cyclophosphamide given through the drinking water.
  • Combination of LDM cyclophosphamide with tirapazamine results in significantly improved tumor control in the PC-3, HT-29 colon adenocarcinoma, and MDA-MB-231 breast cancer human xenograft models without having a negative effect on the favorable toxicity profile of LDM cyclophosphamide.
  • [MeSH-minor] Animals. Breast Neoplasms / blood supply. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Growth Processes / drug effects. Cell Hypoxia / physiology. Cell Line, Tumor. Colonic Neoplasms / blood supply. Colonic Neoplasms / drug therapy. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Female. Humans. Male. Mice. Mice, Inbred BALB C. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology. Oxygen / metabolism. Prostatic Neoplasms / blood supply. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Triazines / administration & dosage. Triazines / toxicity. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452226.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 41233
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Triazines; 1UD32YR59G / tirapazamine; 8N3DW7272P / Cyclophosphamide; S88TT14065 / Oxygen
  •  go-up   go-down


15. Zeitoun G: [Cellular and molecular deregulations driving the metastatic phenotype]. Med Sci (Paris); 2009 Mar;25 Spec No 1:29-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Dérèglements cellulaires et moléculaires à l'origine du phénotype métastatique.
  • Chromosomal instability is the most frequent characteristics of colon adenocarcinoma, and is observed in distant metastatic foci.
  • [MeSH-major] Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Neoplasm Metastasis / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361408.001).
  • [ISSN] 0767-0974
  • [Journal-full-title] Médecine sciences : M/S
  • [ISO-abbreviation] Med Sci (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


16. Kohno H, Suzuki R, Yasui Y, Miyamoto S, Wakabayashi K, Tanaka T: Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice. Clin Cancer Res; 2007 Apr 15;13(8):2519-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice.
  • In the current study, we investigated whether ursodeoxycholic acid (UDCA) can inhibit colitis-related mouse colon carcinogenesis and compared it with the effects of sulfasalazine.
  • At week 20, the tumor-inhibitory effects of both chemicals were assessed by counting the incidence and multiplicity of colonic neoplasms.
  • The immunohistochemical expression of the proliferating cell nuclear antigen labeling index in colonic epithelial malignancies was also assessed.
  • RESULTS: Feeding the mice with UDCA at all doses significantly inhibited the multiplicity of colonic adenocarcinoma.
  • The treatment also significantly lowered the proliferating cell nuclear antigen labeling index in the colonic malignancies.
  • UDCA feeding reduced the expression of inducible nitric oxide synthase and tumor necrosis factor-alpha mRNA in the colonic mucosa, while not significantly affecting the expression of cyclooxygenase-2 mRNA and peroxisome proliferator-activated receptor-gamma mRNA.
  • Sulfasalazine caused a nonsignificant reduction in the incidence and multiplicity of colonic neoplasia and did not affect these mRNA expression.
  • CONCLUSIONS: Our findings suggest that UDCA rather than sulfasalazine could serve as an effective suppressing agent in colitis-related colon cancer development in mice.
  • [MeSH-major] Colitis / complications. Colonic Neoplasms / etiology. Colonic Neoplasms / prevention & control. Sulfasalazine / therapeutic use. Ursodeoxycholic Acid / therapeutic use

  • Hazardous Substances Data Bank. SULFASALAZINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17438113.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / RNA, Messenger; 3XC8GUZ6CB / Sulfasalazine; 724L30Y2QR / Ursodeoxycholic Acid; EC 1.14.99.1 / Cyclooxygenase 2; MO0N1J0SEN / Azoxymethane
  •  go-up   go-down


17. Trafalis DT, Geromichalos GD, Bountouroglou N, Koumbi D, Kontos M, Sougias D, Dalezis P, Karamanakos P, Papageorgiou A, Camoutsis C, Athanassiou AE: A preclinical survey on the efficacy of lactandrate in the treatment of colon carcinoma. J BUON; 2005 Apr-Jun;10(2):227-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A preclinical survey on the efficacy of lactandrate in the treatment of colon carcinoma.
  • PURPOSE: There has been a recent and dramatic increase in the pace of drug development for colorectal cancer which holds promise to further improve curative therapy.
  • We tested lactandrate, an alkylating ester of D-lactam androsterone, for antineoplastic activity against colon adenocarcinoma in vitro and in vivo.
  • MATERIALS AND METHODS: The cytostatic and cytotoxic activity of lactandrate were evaluated in vitro against 9 human colon adenocarcinoma cell lines.
  • The in vivo antitumour effect was determined against two rodent colon carcinomas, the Colon 26 and the relatively chemoresistant Colon 38 carcinoma, as well as against the human xenograft CX-1 colon carcinoma.
  • RESULTS: Lactandrate displayed a satisfactory activity against the 9 human colon cancer cell lines, inducing significant growth inhibition and cytotoxicity.
  • Lactandrate induced antiproliferative activity against colon cancer cell lines linearly correlated with the carcinoembryonic antigen (CEA) production.
  • In vivo, the compound produced a significant antitumour activity against Colon 26 and Colon 38, as well as a moderate antitumour effect against CX-1 colon carcinoma.
  • CONCLUSION: Preclinical research supports the high in vitro and in vivo antitumour potential of lactandrate against colon carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343334.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


18. Li X, Qi X, Zhou L, Fu W, Abdul-Karim FW, Maclennan G, Gorodeski GI: P2X(7) receptor expression is decreased in epithelial cancer cells of ectodermal, uro-genital sinus, and distal paramesonephric duct origin. Purinergic Signal; 2009 Sep;5(3):351-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P2X(7) receptor expression is decreased in epithelial cancer cells of ectodermal, uro-genital sinus, and distal paramesonephric duct origin.
  • The aim of the present study was to better understand the biological significance of P2X(7) receptor expression in normal and cancer human epithelial tissues.
  • P2X(7) receptor and messenger RNA (mRNA) levels were determined in human tissues containing epithelial dysplastic, pre- or early cancerous, and cancer cells, and the levels were compared to those in the corresponding normal epithelial cells within the same tissue of the same case.
  • P2X(7) receptor levels in cancer cells were similar (colon adenocarcinoma) or greater (thyroid papillary carcinoma) than those in the corresponding normal cells.
  • In contrast, in cancer cells of the ectocervix (squamous), endocervix and endometrium (adenocarcinoma), urinary bladder (transitional cell carcinoma), and breast (ductal and lobular adenocarcinomas), P2X(7) receptor levels were lower by about twofold than those in the corresponding normal epithelial cells.
  • Similarly, P2X(7) mRNA levels were lower in uterine, bladder, and breast cancer epithelial tissues by about fourfold than those in the corresponding normal tissues.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1996 May 3;272(5262):735-8 [8614837.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jan;83(1):1-10 [14997049.001]
  • [Cites] Am J Physiol. 1993 Sep;265(3 Pt 1):C577-606 [8214015.001]
  • [Cites] J Biol Chem. 2008 Oct 17;283(42):28274-86 [18682393.001]
  • [Cites] Endocrinology. 2008 Jan;149(1):389-96 [17947359.001]
  • [Cites] Mol Pharmacol. 2007 Dec;72(6):1447-56 [17785580.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):233-43 [17482244.001]
  • [Cites] FEBS Lett. 2007 Feb 6;581(3):483-8 [17240370.001]
  • [Cites] Curr Pharm Des. 2006;12(34):4411-25 [17168751.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):1045-9 [17065062.001]
  • [Cites] Semin Cancer Biol. 2006 Oct;16(5):344-7 [16914325.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7386-9 [16885331.001]
  • [Cites] J Biol Chem. 2006 Jun 23;281(25):17228-37 [16624800.001]
  • [Cites] Histopathology. 2004 Mar;44(3):206-15 [14987223.001]
  • [Cites] J Neurosci. 2003 Oct 1;23(26):8903-10 [14523092.001]
  • [Cites] J Invest Dermatol. 2003 Aug;121(2):315-27 [12880424.001]
  • [Cites] Aging Cell. 2003 Feb;2(1):39-45 [12882333.001]
  • [Cites] Melanoma Res. 2003 Apr;13(2):137-45 [12690296.001]
  • [Cites] Cell Physiol Biochem. 2003;13(2):93-102 [12649594.001]
  • [Cites] FEBS Lett. 2003 Mar 13;538(1-3):159-62 [12633871.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4590-6 [12464620.001]
  • [Cites] Physiol Rev. 2002 Oct;82(4):1013-67 [12270951.001]
  • [Cites] J Biol Chem. 2001 Jun 29;276(26):23262-7 [11313357.001]
  • [Cites] J Biol Chem. 2000 Sep 1;275(35):26792-8 [10854431.001]
  • [Cites] J Urol. 2000 Jun;163(6):2002-7 [10799247.001]
  • [Cites] Oral Oncol. 1999 Nov;35(6):541-7 [10705087.001]
  • [Cites] J Clin Immunol. 1999 Nov;19(6):350-64 [10634209.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):1-2 [16434576.001]
  • [Cites] J Invest Dermatol. 2005 Sep;125(3):482-90 [16117789.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 24;332(1):17-27 [15896293.001]
  • [Cites] Endocrinology. 2005 Jan;146(1):164-74 [15459114.001]
  • [Cites] Endocrinology. 2004 Dec;145(12):5568-79 [15319352.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] J Cell Biol. 1997 Dec 29;139(7):1635-43 [9412459.001]
  • [Cites] Br J Pharmacol. 1999 Aug;127(8):1915-21 [10482924.001]
  • [Cites] Cell Tissue Res. 1999 Jun;296(3):599-605 [10370147.001]
  • [Cites] Cell Biochem Biophys. 1998;29(3):281-306 [9868583.001]
  • [Cites] Receptors Channels. 1998;5(6):347-54 [9826911.001]
  • [Cites] Neurochem Int. 1998 Sep;33(3):209-15 [9759915.001]
  • [Cites] Pharmacol Rev. 1998 Sep;50(3):413-92 [9755289.001]
  • [Cites] Cell Biol Toxicol. 1998 Mar;14(2):111-20 [9553722.001]
  • [Cites] J Immunol. 1997 Aug 1;159(3):1451-8 [9233643.001]
  • [Cites] Physiol Rev. 1997 Apr;77(2):397-424 [9114819.001]
  • [Cites] Annu Rev Cell Biol. 1991;7:663-98 [1809356.001]
  • [Cites] Arch Toxicol. 1991;65(6):437-44 [1929863.001]
  • [Cites] Int Rev Cytol. 1980;68:251-306 [7014501.001]
  • [Cites] J Invest Dermatol. 1972 Sep;59(3):251-9 [5055188.001]
  • [Cites] Am J Physiol. 1995 May;268(5 Pt 1):C1215-26 [7762615.001]
  • (PMID = 19399640.001).
  • [ISSN] 1573-9538
  • [Journal-full-title] Purinergic signalling
  • [ISO-abbreviation] Purinergic Signal.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R01 AG015955
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2717318
  •  go-up   go-down


19. Rénert AF, Leprince P, Dieu M, Renaut J, Raes M, Bours V, Chapelle JP, Piette J, Merville MP, Fillet M: The proapoptotic C16-ceramide-dependent pathway requires the death-promoting factor Btf in colon adenocarcinoma cells. J Proteome Res; 2009 Oct;8(10):4810-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The proapoptotic C16-ceramide-dependent pathway requires the death-promoting factor Btf in colon adenocarcinoma cells.
  • They are involved in the regulation of cancer-cell growth, differentiation, senescence and apoptosis.
  • To better understand how these secondary messengers induce their biological effects, adenocarcinoma cells (HCT116) were treated with exogenous long-chain ceramides (C16-ceramide) in order to mimic endogenous sphingolipids.
  • In adenocarcinoma cells, Btf regulates apoptosis related proteins such as Mdm2, p53, BAX and pBcl-2 and thus plays an important role in the ceramide mediated cell death.
  • [MeSH-major] Adenocarcinoma / metabolism. Ceramides / pharmacology. Colonic Neoplasms / metabolism. Proteomics / methods. Repressor Proteins / metabolism. Tumor Suppressor Proteins / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19705920.001).
  • [ISSN] 1535-3907
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / BCLAF1 protein, human; 0 / Ceramides; 0 / Proteome; 0 / Repressor Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / bcl-2-Associated X Protein; 4201-58-5 / N-palmitoylsphingosine; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


20. Harada O, Suga T, Suzuki T, Nakamoto K, Kobayashi M, Nomiyama T, Nadano D, Ohyama C, Fukuda MN, Nakayama J: The role of trophinin, an adhesion molecule unique to human trophoblasts, in progression of colorectal cancer. Int J Cancer; 2007 Sep 1;121(5):1072-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of trophinin, an adhesion molecule unique to human trophoblasts, in progression of colorectal cancer.
  • Here, we report that trophinin is expressed in tumors from 64% of colon cancer patients (n = 50) and high trophinin expression is closely associated with poor prognosis.
  • To determine the link between trophinin expression and malignancy, colon adenocarcinoma SW480 cells were stably transfected with trophinin.
  • Immunohistochemical analysis of tumors from the colorectal cancer patients confirmed positive correlation of HMGB1 protein expression in the nucleus to trophinin expression in tumor.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Adhesion Molecules / physiology. Colorectal Neoplasms / pathology. Neoplasm Invasiveness. Trophoblasts / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17487845.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD 34108
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Advanced Glycosylation End Product-Specific Receptor; 0 / BYSL protein, human; 0 / Cell Adhesion Molecules; 0 / DNA Primers; 0 / DNA, Complementary; 0 / HMGB1 Protein; 0 / Receptors, Immunologic; 0 / TRO protein, human; 0 / TROAP protein, human
  •  go-up   go-down


21. Wai PY, Mi Z, Guo H, Sarraf-Yazdi S, Gao C, Wei J, Marroquin CE, Clary B, Kuo PC: Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis; 2005 Apr;26(4):741-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis.
  • Hepatic metastasis is a primary cause for failure of locoregional therapy in colorectal cancer.
  • Increased expression of osteopontin (OPN), a ligand for alpha(v)beta3 integrin and CD44 receptors, is associated with metastasis in several types of cancer.
  • However, the mechanism by which OPN mediates metastasis in colorectal cancer remains unknown.
  • We hypothesized that OPN mediates invasion of colon cancer cells through basement membrane and migration through extracellular matrix (ECM).
  • In this study, we used CT26 murine colon adenocarcinoma cells syngeneic to BALB/c mice to generate cell lines (pS-OPN) in which OPN expression was suppressed through small interfering RNA (siRNA) plasmids.
  • This study demonstrates that RNA interference stably reduces CT26 tumor expression of OPN and significantly attenuates CT26 colon cancer metastasis by diminishing tumor cell motility and invasiveness.
  • [MeSH-major] Adenocarcinoma / therapy. Colonic Neoplasms / therapy. Gene Silencing / drug effects. Liver Neoplasms / therapy. RNA, Small Interfering / physiology. Sialoglycoproteins / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661802.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R01AI44629; United States / NIGMS NIH HHS / GM / R01GM65113
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / Sialoglycoproteins; 0 / Spp1 protein, mouse; 106441-73-0 / Osteopontin; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


22. Huang L, Song M, Yang HS, Zhang YG, Hu HZ: [Cloning, expression, distribution and subcellular localization of AK078438 gene]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Jun;24(3):271-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The full open reading frame of AK078438 gene with 1065 bp, 355aa were identified. mRNA of the gene distributed in brain, uterus, colon, bone marrow, testis and kidney, but not in stomach, liver, the lung, spleen and heart.
  • Murine colon adenocarcinoma C26, melanoma B16, Lewis lung carcinoma LL/2 and MSC had the gene and mouse myeloma cell line NS-1 and Hepa mouse hepatoma cell line had no the gene.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17557235.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proteins; 0 / RNA, Messenger
  •  go-up   go-down


23. Carson HJ, Krivit JS, Eilers SG: Metastasis of colonic adenocarcinoma to the external ear canal: an unusual case with a complex-pattern of disease progression. Ear Nose Throat J; 2005 Jan;84(1):36-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of colonic adenocarcinoma to the external ear canal: an unusual case with a complex-pattern of disease progression.
  • We report on a patient who developed far-ranging metastases of adenocarcinoma of the colon that followed a gradual cephalad progression, including the right external ear canal, and led to hearing loss.
  • The patient was a 63-year-old white male with stage III adenocarcinoma of the colon.
  • Physical examination of the head and neck showed a mass in the external ear canal, and biopsy confirmed adenocarcinoma.
  • The significance of such wide-ranging metastases is that metastasis of adenocarcinoma to the ear did not signal imminent death, and relief of the hearing loss it caused was possible.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Ear Canal. Ear Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742771.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Kim KY, Kee MK, Chong SA, Nam MJ: Galanin is up-regulated in colon adenocarcinoma. Cancer Epidemiol Biomarkers Prev; 2007 Nov;16(11):2373-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galanin is up-regulated in colon adenocarcinoma.
  • The early diagnosis of colorectal cancer and the early detection of recurrence are central to effective treatment, as prognosis is directly related to the stage of the disease.
  • When colorectal cancer is diagnosed at an early, localized stage, 5-year survival is 90%.
  • There is substantial interest in the identification of circulating human tumor-derived proteins in serum for the purposes of early cancer diagnosis.
  • We have implemented an approach based on the analysis of microarray data for the identification of tumor proteins that may have utility as biomarkers in colon cancer.
  • Expression analysis of microarray data obtained from a variety of 290 tumors and normal tissues revealed that galanin was maximally expressed in colon cancer.
  • These findings were corroborated by real-time quantitative PCR, in which the colon cancer cell lines LOVO, HCT15, SW480, and SW620 cell showed significantly higher levels of galanin expression than did noncolon cancer cell lines.
  • To evaluate galanin as a potential biomarker of colon cancer, a preliminary "training" set of serum from 40 healthy donors and 55 colon cancer patients was analyzed by ELISA.
  • The data pattern was confirmed by an independent set of 90 masked serum samples: 24 from healthy donors and 66 from colon cancer patients.
  • These findings justify a prospective assessment of serum galanin protein as a screening tool for colon cancer.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Colonic Neoplasms / blood. Galanin / blood

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006926.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 88813-36-9 / Galanin
  •  go-up   go-down


25. Banzo J, Prats E, Ubieto MA, Alonso V, Razola P, Tardín L, Andrés A, Santapau A: [Liver metastasis in a patient with adenocarcinoma of the colon and typical pulmonary carcinoid tumor]. Rev Esp Med Nucl; 2009 Sep-Oct;28(5):253-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver metastasis in a patient with adenocarcinoma of the colon and typical pulmonary carcinoid tumor].
  • [Transliterated title] Metástasis hepática en un paciente con adenocarcinoma de colon y tumor carcinoide pulmonar típico.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoid Tumor. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms. Neoplasms, Multiple Primary


26. Rivadulla-Serrano MI, Martínez-Ramos D, Armengol-Carrasco M, Escrig-Sos J, Paiva-Coronel GA, Fortea-Sanchís C, Salvador-Sanchís JL: Impact of the total number of harvested lymph nodes after colon cancer resections on survival in patients without involved lymph node. Rev Esp Enferm Dig; 2010 May;102(5):296-301
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of the total number of harvested lymph nodes after colon cancer resections on survival in patients without involved lymph node.
  • BACKGROUND: The total number of harvested lymph nodes has been demonstrated to be of prognostic significance for colon cancer.
  • OBJECTIVE: The aim of this study was to analyse if, in our centre, the number of analysed lymph nodes in patients with colon cancer that are classified as pN0 is also related to survival.
  • MATERIAL AND METHODS: A retrospective study was designed, where 148 patients with colon adenocarcinoma (pN0 of TNM classification) who underwent elective surgery between 1 January 1995 and 31 December 2001, with curative intent were included.
  • CONCLUSION: In our centre, harvesting a larger number of lymph nodes is related to improved rates of 5-years survival for patients with colon cancer staged as pN0.
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Lymph Nodes / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524756.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


27. Wang C, Li N, Liu X, Zheng Y, Cao X: A novel endogenous human CaMKII inhibitory protein suppresses tumor growth by inducing cell cycle arrest via p27 stabilization. J Biol Chem; 2008 Apr 25;283(17):11565-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report the characterization of a novel human endogenous CaMKII inhibitor, human CaMKII inhibitory protein alpha (hCaMKIINalpha), which directly interacts with activated CaMKII and effectively inhibits CaMKII activity. hCaMKIINalpha expression is negatively correlated with the severity of human colon adenocarcinoma.
  • Overexpression of hCaMKIINalpha inhibits colon adenocarcinoma growth in vitro and in vivo by arresting the cell cycle at the S phase through its conserved inhibitory region (27CIR), whereas silencing the hCaMKIINalpha expression accelerates tumor growth and cell cycle progression.
  • The findings underscore a link between hCaMKIINalpha-mediated inhibition of CaMKII activity and p27-dependent pathways in controlling tumor cell growth and cell cycle and imply a potential application of hCaMKIINalpha in the therapeutics of colon cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Calcium-Calmodulin-Dependent Protein Kinase Type 2 / chemistry. Calcium-Calmodulin-Dependent Protein Kinase Type 2 / physiology. Colonic Neoplasms / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / physiology. Gene Expression Regulation, Neoplastic. Neoplasms / metabolism. Proteins / physiology

  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10890-5 [9724800.001]
  • [Cites] Exp Cell Res. 1998 May 1;240(2):218-27 [9596994.001]
  • [Cites] Ann Surg Oncol. 2004 Nov;11(11):955-61 [15525823.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):2865-73 [15687337.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7545-53 [16243830.001]
  • [Cites] Neuroscience. 2001;102(4):767-77 [11182241.001]
  • [Cites] Cell. 2001 May 4;105(3):297-306 [11348589.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Oct;1(1):11-21 [11413485.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jul 13;285(2):229-34 [11444830.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7142-7 [11585747.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1115-22 [11830654.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1153-60 [12244302.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39356-71 [12878607.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45101-8 [12954639.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):11639-48 [14684736.001]
  • [Cites] FEBS Lett. 1988 Apr 25;231(2):445-50 [3360150.001]
  • [Cites] EMBO J. 1991 Aug;10(8):2087-93 [1829675.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Dec 31;181(3):968-75 [1662507.001]
  • [Cites] J Biochem. 1991 Sep;110(3):417-22 [1663112.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Feb 28;199(1):241-8 [8123019.001]
  • [Cites] J Biol Chem. 1995 Feb 3;270(5):2163-70 [7836445.001]
  • [Cites] Mol Cell Biol. 1995 May;15(5):2612-24 [7739542.001]
  • [Cites] Biochem Cell Biol. 1995 Mar-Apr;73(3-4):201-7 [7576494.001]
  • [Cites] Cell Growth Differ. 1995 Sep;6(9):1063-70 [8519682.001]
  • [Cites] EMBO J. 1996 Aug 15;15(16):4182-93 [8861947.001]
  • [Cites] Nat Med. 1997 Feb;3(2):231-4 [9018245.001]
  • [Cites] Oncogene. 1997 Aug 7;15(6):629-37 [9264403.001]
  • [Cites] FASEB J. 1997 Nov;11(13):1067-75 [9367342.001]
  • [Cites] Science. 1998 Jan 9;279(5348):227-30 [9422695.001]
  • [Cites] J Biol Chem. 1999 Mar 19;274(12):7958-68 [10075693.001]
  • (PMID = 18305109.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CAMK2N1 protein, human; 0 / Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinase Type 2
  • [Other-IDs] NLM/ PMC2431061
  •  go-up   go-down


28. Wang X, Chen W, Li X, Lin H, Wang Q: Heat shock protein 72 associated with CD44v6 in human colonic adenocarcinoma. Cell Biol Int; 2008 Jul;32(7):860-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heat shock protein 72 associated with CD44v6 in human colonic adenocarcinoma.
  • CD44v6 is a splice variant of CD44 (CD44v), probably promoting cancer cell adherence to vascular endothelium and base membranes and enhancing the invasion and metastasis of colonic carcinomas.
  • There may be a possible association between the expression of HSP72 and CD44v6 during the growth and progression of colonic carcinoma cells.
  • The aim of the study was to investigate the interaction between heat shock protein 72 and CD44v6 in human colonic carcinomas.
  • The localization of HSP72 and CD44v6 in human colonic carcinomas was determined by immunohistochemistry and confocal laser microscopy.
  • The interaction between HSP72 and CD44v6 in colonic carcinoma cells was analyzed by immunoprecipitation and Western immunoblots.
  • Our results revealed that colonic carcinoma synchronously co-expressed higher levels of HSP72 and CD44v6 than that in adjacent normal colonic tissues.
  • Based on immunoprecipitation and Western immunoblots, we found that HSP72 was associated with CD44v6 precursor fragments in human colonic carcinoma cells.
  • The interaction between HSP72 and CD44v6 in human colonic carcinoma cells may contribute to study the pathogenesis and immunotherapy of colonic carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, CD44 / metabolism. Colonic Neoplasms / metabolism. HSP72 Heat-Shock Proteins / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18387829.001).
  • [ISSN] 1065-6995
  • [Journal-full-title] Cell biology international
  • [ISO-abbreviation] Cell Biol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / HSP72 Heat-Shock Proteins; 0 / Protein Isoforms
  •  go-up   go-down


29. Nguyen H, Loustaunau C, Facista A, Ramsey L, Hassounah N, Taylor H, Krouse R, Payne CM, Tsikitis VL, Goldschmid S, Banerjee B, Perini RF, Bernstein C: Deficient Pms2, ERCC1, Ku86, CcOI in field defects during progression to colon cancer. J Vis Exp; 2010;(41)
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deficient Pms2, ERCC1, Ku86, CcOI in field defects during progression to colon cancer.
  • Such field defects have been indicated in colon cancer.
  • The molecular abnormalities that are responsible for a field defect in the colon should be detectable at high frequency in the histologically normal tissue surrounding a colonic adenocarcinoma or surrounding an adenoma with advanced neoplasia (well on the way to a colon cancer), but at low frequency in the colonic mucosa from patients without colonic neoplasia.
  • Using immunohistochemistry, entire crypts within 10 cm on each side of colonic adenocarcinomas or advanced colonic neoplasias were found to be frequently reduced or absent in expression for two DNA repair proteins, Pms2 and/or ERCC1.
  • The reduced or absent expression of both ERCC1 and Pms2 is likely an early step in progression to colon cancer.
  • DNA repair gene Ku86 (active in DNA non-homologous end joining) and Cytochrome c Oxidase Subunit I (involved in apoptosis) had each been reported to be decreased in expression in mucosal areas close to colon cancers.
  • However, immunohistochemical evaluation of their levels of expression showed only low to modest frequencies of crypts to be deficient in their expression in a field defect surrounding colon cancer or surrounding advanced colonic neoplasia.
  • We show that frequency of entire crypts deficient for Pms2 and ERCC1 is often as great as 70% to 95% in 20 cm long areas surrounding a colonic neoplasia, while frequency of crypts deficient in Ku86 has a median value of 2% and frequency of crypts deficient in CcOI has a median value of 16% in these areas.
  • The entire colon is 150 cm long (about 5 feet) and has about 10 million crypts in its mucosal layer.
  • The defect in Pms2 and ERCC1 surrounding a colon cancer thus may include 1 million crypts.
  • It is from a defective crypt that colon cancer arises.
  • [MeSH-major] Adenosine Triphosphatases / deficiency. Colonic Neoplasms / metabolism. Cytochrome-c Oxidase Deficiency / metabolism. DNA Repair Enzymes / deficiency. DNA-Binding Proteins / deficiency. Endonucleases / deficiency. Precancerous Conditions / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Jan 1;61(1):50-2 [11196196.001]
  • [Cites] Lancet Oncol. 2000 Sep;1(1):15-6 [11905680.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5441-9 [12154406.001]
  • [Cites] Am J Pathol. 2004 Apr;164(4):1447-53 [15039232.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3382-9 [19336570.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):714-9 [16407113.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Jun;14(2):166-72 [16785784.001]
  • [Cites] Carcinogenesis. 2007 Jan;28(1):215-22 [16887864.001]
  • [Cites] Cancer Lett. 2008 Feb 18;260(1-2):1-10 [18164807.001]
  • [Cites] Gastroenterology. 2008 Dec;135(6):2128-40, 2140.e1-8 [18801366.001]
  • [Cites] Mutat Res. 2005 Jan;589(1):47-65 [15652226.001]
  • (PMID = 20689513.001).
  • [ISSN] 1940-087X
  • [Journal-full-title] Journal of visualized experiments : JoVE
  • [ISO-abbreviation] J Vis Exp
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Video-Audio Media
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / DNA-Binding Proteins; 0 / Ku autoantigen; EC 1.9.3.1 / Electron Transport Complex IV; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / PMS2 protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ PMC3149991
  •  go-up   go-down


30. Ruan WJ, Lin J, Xu EP, Xu FY, Ma Y, Deng H, Huang Q, Lv BJ, Hu H, Cui J, Di MJ, Dong JK, Lai MD: IGFBP7 plays a potential tumor suppressor role against colorectal carcinogenesis with its expression associated with DNA hypomethylation of exon 1. J Zhejiang Univ Sci B; 2006 Nov;7(11):929-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Insulin-like growth factor binding-protein-7 (IGFBP7) was obtained from our previous colonic adenocarcinoma (CRC) and normal mucosa suppression subtraction hybridization (SSH) cDNA libraries.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. DNA Methylation. Insulin-Like Growth Factor Binding Proteins / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pathol. 2001 Oct;54(5):285-8 [11577168.001]
  • [Cites] Int J Cancer. 2001 Jul 20;95(4):216-22 [11400113.001]
  • [Cites] Cell Growth Differ. 2002 May;13(5):205-13 [12065244.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):665-72 [12163391.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3410-5 [12624183.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3A):2043-51 [12894577.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7717-23 [14633696.001]
  • [Cites] Endocr Relat Cancer. 2004 Mar;11(1):141-8 [15027891.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6789-95 [15501955.001]
  • [Cites] Cell Growth Differ. 1993 Sep;4(9):715-22 [7694637.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):12981-6 [9371786.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Apr;84(4):1283-7 [10199768.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2370-5 [10344746.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2787-90 [10383131.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):102-8 [15598946.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jan 7;267(1):109-17 [10623583.001]
  • [Cites] Mol Med. 2000 Feb;6(2):126-35 [10859029.001]
  • [Cites] World J Gastroenterol. 2001 Oct;7(5):726-31 [11819864.001]
  • (PMID = 17048309.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Proteins; 0 / Tumor Suppressor Proteins; 0 / insulin-like growth factor binding protein-related protein 1
  • [Other-IDs] NLM/ PMC1635813
  •  go-up   go-down


31. Mayeur C, Veuillet G, Michaud M, Raul F, Blottière HM, Blachier F: Effects of agmatine accumulation in human colon carcinoma cells on polyamine metabolism, DNA synthesis and the cell cycle. Biochim Biophys Acta; 2005 Aug 15;1745(1):111-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of agmatine accumulation in human colon carcinoma cells on polyamine metabolism, DNA synthesis and the cell cycle.
  • Using the human colon adenocarcinoma HT-29 Glc(-/+) cell line, we demonstrate that agmatine, which markedly accumulated inside the cells without being metabolised, exerted a strong cytostatic effect with an IC50 close to 2 mM.
  • [MeSH-major] Agmatine / pharmacology. Cell Cycle / drug effects. Colonic Neoplasms / metabolism. DNA Replication / drug effects. DNA, Neoplasm / biosynthesis. Polyamines / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16085059.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Polyamines; 70J407ZL5Q / Agmatine; EC 4.1.1.17 / Ornithine Decarboxylase
  •  go-up   go-down


32. Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N: Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol; 2008 Sep;15(9):2388-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a difference in survival between right- versus left-sided colon cancers?
  • BACKGROUND: The incidence of right-sided colon cancers has been increasing in recent years.
  • In this study, we have compared the survival of right-and left-sided colon cancers in a longitudinal population-based database.
  • METHODS: A retrospective survival analysis was performed using the Surveillance, Epidemiology, and End Results Program (SEER) database between 1988 and 2003 on subjects who underwent surgical resection for the a primary diagnosis of pathologically confirmed invasive colon adenocarcinoma.
  • Cox proportional hazard regression analysis was used to assess long-term survival outcomes comparing right-sided (cecum to transverse colon, excluding appendix) versus left-sided (splenic flexure to sigmoid, excluding rectum) colon cancers.
  • RESULTS: A total of 77,978 subjects were identified with adenocarcinoma of the colon.
  • By Cox proportional hazard regression analysis, controlling for statistically significant confounders, including age, sex, race, marital status, tumor stage, tumor size, histologic grade, number of lymph nodes examined, and year of diagnosis, right-sided colon cancers were associated with a 5% increased mortality risk compared with left-sided colon cancers (hazard ratio, 1.04; 95% confidence interval, 1.02-1.07).
  • CONCLUSION: On the basis of analysis of information from the SEER database, we found that right-sided colon cancers have a worse prognosis than left-sided colon cancers.
  • The reason for this remains unclear but may be due to biological and/or environmental factors and may have particular bearing, given the rising incidence of right-sided colon cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Dis. 1997 Jul-Oct;15(4-5):302-11 [9359018.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2343-50 [8635041.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):46-50 [8508429.001]
  • [Cites] Dis Colon Rectum. 1991 Jan;34(1):56-9 [1991421.001]
  • [Cites] Langenbecks Arch Chir. 1987;371(3):193-200 [2446097.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):755-62 [12917207.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):403-8 [12216066.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):609-18 [15659508.001]
  • [Cites] Gut. 2005 Mar;54(3):374-84 [15710986.001]
  • [Cites] Br J Surg. 1998 Feb;85(2):246-8 [9501827.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3831-9 [17606714.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Surg Oncol. 2004 Dec 15;88(4):261-6 [15565587.001]
  • (PMID = 18622647.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK007713-13; United States / NIDDK NIH HHS / DK / T32 DK007713; United States / NIDDK NIH HHS / DK / T32 DK007713-13; United States / NIDDK NIH HHS / DK / T32DK007713
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS280426; NLM/ PMC3072702
  •  go-up   go-down


33. Azzali G: On the transendothelial passage of tumor cell from extravasal matrix into the lumen of absorbing lymphatic vessel. Microvasc Res; 2006 Jul-Sep;72(1-2):74-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the research is the study of ultrastructural characteristics of the absorbing lymphatic vessel and of tumor cell passage through the endothelial lymphatic wall in (a) subcutaneous xenografts of T84 colon adenocarcinoma and B16 melanoma cell lines in nude mice and (b) human colorectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16730031.001).
  • [ISSN] 0026-2862
  • [Journal-full-title] Microvascular research
  • [ISO-abbreviation] Microvasc. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Karabay CY, Biteker M, Zehir R, Bezgin T, Tanboga H, Can MM, Güler A, Duran NE, Ozkan M: Multiple spontaneous coronary artery dissection associated with Trousseau's syndrome. Cardiol J; 2010;17(6):625-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein, we present a 57 year-old man who developed SCAD concomitant with Trousseau's syndrome secondary to colon adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / complications. Aneurysm, Dissecting / etiology. Colonic Neoplasms / complications. Coronary Aneurysm / etiology. Paraneoplastic Syndromes / etiology. Venous Thrombosis / etiology

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21154268.001).
  • [ISSN] 1897-5593
  • [Journal-full-title] Cardiology journal
  • [ISO-abbreviation] Cardiol J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


35. Robinson B, Frizelle F, Dickson M, Frampton C: Colorectal cancer treated at Christchurch Hospital, New Zealand: a comparison of 1993 and 1998 cohorts. N Z Med J; 2005 Feb 25;118(1210):U1323
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal cancer treated at Christchurch Hospital, New Zealand: a comparison of 1993 and 1998 cohorts.
  • AIM: To compare clinicopathological variables, management, and outcome of two cohorts of unselected patients treated for colorectal cancer (CRC) at Christchurch Hospital, New Zealand in 1993-94 and 1998-99.
  • RESULTS: 356 patients in 1993-94 and 317 patients in 1998-99 had a confirmed diagnosis of adenocarcinoma of the colon or rectum.
  • [MeSH-major] Adenocarcinoma / surgery. Colorectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] N Z Med J. 2005 Feb 25;118(1210):U1330 [15776102.001]
  • (PMID = 15776099.001).
  • [ISSN] 1175-8716
  • [Journal-full-title] The New Zealand medical journal
  • [ISO-abbreviation] N. Z. Med. J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


36. Nazim-Zygadło E, Dobosz P, Kochanowicz J, Czajecki K: [Metastasis from a colonic adenocarcinoma to the sphenoid sinus]. Otolaryngol Pol; 2005;59(3):429-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastasis from a colonic adenocarcinoma to the sphenoid sinus].
  • The authors present a very rare disease--metastasis of colon adenocarcinoma to the sphenoid sinus based on their own case.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Paranasal Sinus Neoplasms / radiography. Paranasal Sinus Neoplasms / secondary. Sphenoid Sinus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16117403.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


37. Patel AA, Gupta D, Seligson D, Hattab EM, Balis UJ, Ulbright TM, Kohane IS, Berman JJ, Gilbertson JR, Dry S, Schirripa O, Yu H, Becich MJ, Parwani AV, Shared Pathology Informatics Network: Availability and quality of paraffin blocks identified in pathology archives: a multi-institutional study by the Shared Pathology Informatics Network (SPIN). BMC Cancer; 2007 Feb 28;7:37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Each site generated a list of 100 common tumor cases (25 cases each of breast adenocarcinoma, colonic adenocarcinoma, lung squamous carcinoma, and prostate adenocarcinoma) and 100 rare tumor cases (25 cases each of adrenal cortical carcinoma, gastro-intestinal stromal tumor [GIST], adenoid cystic carcinoma, and mycosis fungoides) using a combination of Tumor Registry, laboratory information system (LIS) and/or SPIN-related tools.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1843-9 [11448894.001]
  • [Cites] Mol Diagn. 2000 Dec;5(4):287-99 [11172493.001]
  • [Cites] Arch Pathol Lab Med. 1996 Oct;120(10):909-12 [12046602.001]
  • [Cites] Am J Clin Pathol. 2002 Dec;118(6):870-6 [12472280.001]
  • [Cites] AMIA Annu Symp Proc. 2003;:584-8 [14728240.001]
  • [Cites] AMIA Annu Symp Proc. 2003;:937 [14728442.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):176-86 [14983930.001]
  • [Cites] J Urol. 2004 Apr;171(4):1393-401 [15017184.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1115-9 [15026787.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4614-21 [15269132.001]
  • [Cites] Stud Health Technol Inform. 2004;107(Pt 1):607-10 [15360884.001]
  • [Cites] Stud Health Technol Inform. 2004;107(Pt 1):663-7 [15360896.001]
  • [Cites] Stud Health Technol Inform. 2004;107(Pt 2):1264-7 [15361017.001]
  • [Cites] Cancer. 1996 Jul 1;78(1):1-3 [8646703.001]
  • [Cites] Urology. 1996 Nov;48(5):773-7 [8911524.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1065-76 [9870854.001]
  • [Cites] Science. 1998 Dec 18;282(5397):2165-6 [9890818.001]
  • [Cites] Diagn Mol Pathol. 1998 Aug;7(4):202-8 [9917130.001]
  • [Cites] Arch Pathol Lab Med. 1999 Apr;123(4):296-300 [10320140.001]
  • [Cites] Clin Lab Med. 2004 Dec;24(4):913-43, vi [15555749.001]
  • [Cites] BMC Cancer. 2005;5:108 [16111498.001]
  • [Cites] BMC Med Inform Decis Mak. 2006;6:12 [16515714.001]
  • [Cites] AMIA Annu Symp Proc. 2005;:515-9 [16779093.001]
  • [Cites] BMC Cancer. 2006;6:120 [16677389.001]
  • [Cites] Community Genet. 1999;2(2-3):51-60 [11787507.001]
  • (PMID = 17386082.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01CA091343; United States / NCI NIH HHS / CA / U01 CA091429; United States / NCI NIH HHS / CA / U01CA091429; United States / NCI NIH HHS / CA / P30 CA016042; United States / NCI NIH HHS / CA / U01 CA091343; United States / NCI NIH HHS / CA / UO1CA91338-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1810540
  •  go-up   go-down


38. Yaoita H, Ohkawara H, Uekita H, Mitsugi M, Tajima H, Kaneko H, Hoshino Y, Otani S, Gotoh M, Maruyama Y: Low serum ferritin levels as a clue to colonic cancer detection in two patients with coronary artery disease: a case report. Fukushima J Med Sci; 2005 Dec;51(2):95-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low serum ferritin levels as a clue to colonic cancer detection in two patients with coronary artery disease: a case report.
  • We diagnosed colonic cancer using low serum ferritin levels as a clue in two patients with cardiac or cardiopulmonary disease.
  • In both patients, PET documented abnormal tracer accumulation in the colon.
  • A colonic adenocarcinoma was detected at the site of the positive PET finding in each patient.
  • Both patients underwent curative resection of the cancer.
  • The detection of the levels of serum ferritin may be available for the screening colonic cancer in patients declining colonoscopic examination.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Coronary Artery Disease / complications. Ferritins / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Aged. Colonoscopy. Humans. Male. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16555630.001).
  • [ISSN] 0016-2590
  • [Journal-full-title] Fukushima journal of medical science
  • [ISO-abbreviation] Fukushima J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 9007-73-2 / Ferritins
  •  go-up   go-down


39. Mikes J, Kleban J, Sacková V, Horváth V, Jamborová E, Vaculová A, Kozubík A, Hofmanová J, Fedorocko P: Necrosis predominates in the cell death of human colon adenocarcinoma HT-29 cells treated under variable conditions of photodynamic therapy with hypericin. Photochem Photobiol Sci; 2007 Jul;6(7):758-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Necrosis predominates in the cell death of human colon adenocarcinoma HT-29 cells treated under variable conditions of photodynamic therapy with hypericin.
  • However, here we report the prevalence of necrosis accompanied by suppression of caspase-3 activation in colon adenocarcinoma HT-29 cells exposed to an extensive range of PDT doses evoked by variations in two variables -- hypericin concentration and light dose.
  • Since it is known that Bcl-2 suppression in HT-29 is reversible and linked to the over-expression of mutated p53 and also considering our data, we suggest that the mutation in p53 and events linked to this feature may play a role in cell death signalling in HT-29 colon cancer cells.
  • [MeSH-major] Adenocarcinoma / therapy. Colonic Neoplasms / therapy. Perylene / analogs & derivatives. Photochemotherapy / methods

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PERYLENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609769.001).
  • [ISSN] 1474-905X
  • [Journal-full-title] Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology
  • [ISO-abbreviation] Photochem. Photobiol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


40. Ghittoni G, Caturelli E, Viera FT: Intrabile duct metastasis from colonic adenocarcinoma without liver parenchyma involvement: contrast enhanced ultrasonography detection. Abdom Imaging; 2010 Jun;35(3):346-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrabile duct metastasis from colonic adenocarcinoma without liver parenchyma involvement: contrast enhanced ultrasonography detection.
  • It is well-known that biliary duct invasion with intraluminal growth is one of the developmental patterns of primary liver tumors, and macroscopic intrabiliary growth of liver metastases in colorectal cancer is found with high frequency.
  • We describe the first recorded case of a metastasis from colorectal cancer involving solely the common hepatic biliary duct, without invasion of contiguous liver parenchyma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Hepatic Duct, Common / pathology. Ultrasonography, Doppler, Color

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19294464.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Flentie KN, Qi M, Gammon ST, Razia Y, Lui F, Marpegan L, Manglik A, Piwnica-Worms D, McKinney JS: Stably integrated luxCDABE for assessment of Salmonella invasion kinetics. Mol Imaging; 2008 Sep-Oct;7(5):222-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bioluminescence reported Salmonella invasion of disparate eukaryotic cell lines, including neoplastic melanoma, colon adenocarcinoma, and glioma cell lines used in animal models of malignancy.

  • MedlinePlus Health Information. consumer health - Salmonella Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microbiol Res. 1996 Dec;151(4):407-19 [9022302.001]
  • [Cites] Mol Microbiol. 1996 Nov;22(4):703-14 [8951817.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Aug;86(16):6383-7 [2548211.001]
  • [Cites] Genetics. 1988 Nov;120(3):645-50 [2852135.001]
  • [Cites] Microbiol Immunol. 1986;30(12):1213-24 [3574155.001]
  • [Cites] FEMS Microbiol Lett. 1998 Jun 15;163(2):193-202 [9673022.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15676-81 [15498871.001]
  • [Cites] Infect Immun. 2005 Jan;73(1):146-54 [15618149.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):755-60 [15644448.001]
  • [Cites] Biotechniques. 2005 Feb;38(2):225-9 [15727129.001]
  • [Cites] Pediatr Res. 2005 Jul;58(1):153-8 [15774831.001]
  • [Cites] Org Biomol Chem. 2005 Oct 7;3(19):3544-50 [16172693.001]
  • [Cites] Infect Immun. 2005 Oct;73(10):7027-31 [16177386.001]
  • [Cites] Methods Enzymol. 2005;399:512-30 [16338379.001]
  • [Cites] Annu Rev Med. 2001;52:259-74 [11160778.001]
  • [Cites] Infect Immun. 2000 Mar;68(3):1400-7 [10678953.001]
  • [Cites] Antimicrob Agents Chemother. 1979 Dec;16(6):743-9 [533256.001]
  • [Cites] Antimicrob Agents Chemother. 1979 Oct;16(4):434-8 [117746.001]
  • [Cites] J Bacteriol. 2004 Apr;186(8):2402-12 [15060043.001]
  • [Cites] Mol Microbiol. 1995 Nov;18(4):593-603 [8817482.001]
  • [Cites] Methods Enzymol. 1994;236:405-20 [7968625.001]
  • [Cites] J Bacteriol. 1994 Aug;176(15):4501-10 [8045880.001]
  • [Cites] Infect Immun. 1991 Dec;59(12):4310-7 [1937792.001]
  • [Cites] Microbiol Rev. 1991 Mar;55(1):123-42 [2030669.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(11):4304-8 [2349239.001]
  • [Cites] J Bacteriol. 2001 Nov;183(22):6620-9 [11673432.001]
  • [Cites] Nature. 2001 Oct 25;413(6858):852-6 [11677609.001]
  • [Cites] Mol Microbiol. 2002 Mar;43(5):1269-83 [11918812.001]
  • [Cites] J Mol Med (Berl). 2002 Jun;80(6):367-76 [12072912.001]
  • [Cites] J Bacteriol. 2002 Nov;184(21):6056-9 [12374840.001]
  • [Cites] Lancet Oncol. 2003 Sep;4(9):548-56 [12965276.001]
  • [Cites] Nat Biotechnol. 2003 Nov;21(11):1307-13 [14528314.001]
  • [Cites] Can J Microbiol. 2003 Sep;49(9):531-7 [14608419.001]
  • [Cites] Annu Rev Genet. 2003;37:3-29 [14616054.001]
  • [Cites] Nucleic Acids Res. 2004;32(2):848-54 [14762212.001]
  • [Cites] Nat Biotechnol. 2004 Mar;22(3):313-20 [14990953.001]
  • [Cites] Cell Microbiol. 2004 Apr;6(4):303-17 [15009023.001]
  • (PMID = 19123992.001).
  • [ISSN] 1535-3508
  • [Journal-full-title] Molecular imaging
  • [ISO-abbreviation] Mol Imaging
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA094056; United States / NINDS NIH HHS / NS / P30 NS057105; United States / NIGMS NIH HHS / GM / GM007067-24; United States / NICHD NIH HHS / HD / HD001487-06; United States / NINDS NIH HHS / NS / P30 NS057105-01; United States / NIGMS NIH HHS / GM / T32 GM007067-24; United States / NICHD NIH HHS / HD / K12 HD001487; United States / NICHD NIH HHS / HD / K12 HD001487-06; United States / NIDDK NIH HHS / DK / P30 DK52574; United States / NCI NIH HHS / CA / P50 CA094056-01; United States / NIGMS NIH HHS / GM / T32 GM007067; United States / NIDDK NIH HHS / DK / P30 DK052574; United States / NIDDK NIH HHS / DK / P30 DK052574-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bacterial Proteins; 0 / Gentamicins; EC 3.6.3.14 / Proton-Translocating ATPases; EC 3.6.3.14 / invC protein, Salmonella typhimurium
  • [Other-IDs] NLM/ NIHMS126229; NLM/ PMC2743400
  •  go-up   go-down


42. Li Y, Wang J, Zhu G, Zhang X, Zhai H, Zhang W, Wang W, Huang G: Detection of parvovirus B19 nucleic acids and expression of viral VP1/VP2 antigen in human colon carcinoma. Am J Gastroenterol; 2007 Jul;102(7):1489-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of parvovirus B19 nucleic acids and expression of viral VP1/VP2 antigen in human colon carcinoma.
  • OBJECTIVES: The aim of this study was to evaluate whether parvovirus B19, a common infectious pathogen in humans, also was involved in human colon carcinoma.
  • METHODS: A total of 119 paraffin-embedded specimens of colon polyps, adenocarcinomas, carcinoma-adjacent tissues, and normal controls were processed for nested polymerase chain reaction (PCR), in situ hybridization (ISH), immunohistochemistry (IHC), and laser capture micro dissection detection of B19 DNA and protein.
  • The expression of cyclo-oxygenase-2 (COX-2) in the colon- cancer cells (Lovo) transfected by inducible vector for VP1u was determined by western-blot analysis.
  • RESULTS: B19 DNA was detected in 94.6% (35/37) of colon adenocarcinomas, 67.6% (25/37) of adjacent noncancerous tissues, 85.6% (30/35) of polyps, and 60.0% (6/10) of normal controls by nested PCR, respectively.
  • Analysis of the microdissected material confirmed the presence of viral DNA in colonic neoplastic epithelium.
  • ISH detected B19 DNA in 81.1% (30/37) of colon adenocarcinomas, 43.2% (16/37) of adjacent noncancerous tissues, 74.3% (26/35) of polyps, and 50.0% (5/10) of normal controls, respectively.
  • B19 protein VP1/VP2 was found in 78.4% (29/37), 32.4% (12/37), and 57.1% (20/35) of colon adenocarcinomas, tumor-adjacent tissues, and polyps, respectively, but not in normal colons (none of 10).
  • There were significant differences in nested PCR, ISH, and IHC between adenocarcinoma and non-neoplastic adjacent tissues, and between adenocarcinoma and normal controls.
  • Transfection of colon-cancer cells (Lovo) by inducible vector for VP1u resulted in marked upregulation of cyclo-oxygenase-2 proteins.
  • CONCLUSIONS: Parvovirus B19 nucleic acids commonly exist in human colon tissues and VP1/VP2 antigen is preferentially located in colon polyps and adenocarcinomas lesions.
  • B19 viral products VP1u may induce important oncogenic pathways in colon-cancer cells.
  • [MeSH-major] Antigens, Viral / biosynthesis. Capsid Proteins / immunology. Carcinoma / virology. Colonic Neoplasms / virology. DNA, Viral / analysis. Parvovirus B19, Human

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17459020.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Capsid Proteins; 0 / DNA, Viral; 0 / capsid protein VP1, parvovirus B19; 0 / capsid protein VP2, parvovirus B19; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


43. Anderson CR, Rychak JJ, Backer M, Backer J, Ley K, Klibanov AL: scVEGF microbubble ultrasound contrast agents: a novel probe for ultrasound molecular imaging of tumor angiogenesis. Invest Radiol; 2010 Oct;45(10):579-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A murine model of colon adenocarcinoma was used to assess retention of scVEGF-MB with contrast ultrasound imaging during tumor angiogenesis in vivo.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):841-8 [16699765.001]
  • [Cites] Invest Radiol. 2006 Mar;41(3):354-62 [16481920.001]
  • [Cites] Bioconjug Chem. 2006 Sep-Oct;17(5):1141-50 [16984121.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2624-33 [17121909.001]
  • [Cites] J Nucl Med. 2006 Dec;47(12):2048-56 [17138749.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):323-30 [17200371.001]
  • [Cites] Nat Med. 2007 Apr;13(4):504-9 [17351626.001]
  • [Cites] Ultrasound Med Biol. 2007 Jun;33(6):950-8 [17434667.001]
  • [Cites] Circulation. 2007 Jul 17;116(3):276-84 [17592078.001]
  • [Cites] Mol Imaging. 2007 Sep-Oct;6(5):289-96 [18092513.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Jan;5(1):44-54 [18097456.001]
  • [Cites] Radiology. 2008 Feb;246(2):508-18 [18180339.001]
  • [Cites] Contrast Media Mol Imaging. 2008 Jan-Feb;3(1):9-18 [18335479.001]
  • [Cites] J Ultrasound Med. 2008 Jun;27(6):855-66 [18499845.001]
  • [Cites] Radiology. 2008 Sep;248(3):936-44 [18710985.001]
  • [Cites] Methods Mol Biol. 2008;494:275-94 [18726580.001]
  • [Cites] Mol Imaging. 2009 Jul-Aug;8(4):209-20 [19728975.001]
  • [Cites] Acad Radiol. 2010 Jan;17(1):54-60 [19815430.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5209-18 [10537299.001]
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):27-34 [10585578.001]
  • [Cites] J Nucl Med. 2000 Jan;41(1):131-40 [10647616.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):3088-95 [10850461.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] Circulation. 2001 Oct 23;104(17):2107-12 [11673354.001]
  • [Cites] Bioconjug Chem. 2001 Nov-Dec;12(6):1066-73 [11716701.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):2010-6 [11747347.001]
  • [Cites] J Clin Invest. 2002 Mar;109(6):777-85 [11901186.001]
  • [Cites] Int J Cancer. 2002 Nov 10;102(2):101-8 [12385004.001]
  • [Cites] Circulation. 2003 Jul 15;108(2):218-24 [12835214.001]
  • [Cites] Circulation. 2003 Jul 22;108(3):336-41 [12835208.001]
  • [Cites] Mol Imaging. 2004 Apr;3(2):125-34 [15296677.001]
  • [Cites] Blood. 1987 Nov;70(5):1284-90 [3663936.001]
  • [Cites] Eur J Cell Biol. 1992 Aug;58(2):271-9 [1425765.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5822-7 [7694795.001]
  • [Cites] Circulation. 1996 Dec 15;94(12):3334-40 [8989148.001]
  • [Cites] Eur J Nucl Med. 1997 Mar;24(3):350-1 [9143478.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):533-9 [15695396.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1423-9 [16170035.001]
  • [Cites] Ultrasound Med Biol. 2005 Sep;31(9):1279-83 [16176794.001]
  • [Cites] J Autoimmun. 2005 Nov;25(3):199-205 [16249069.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):932-6 [16355210.001]
  • [Cites] Gastroenterology. 2006 Jan;130(1):8-16 [16401463.001]
  • [Cites] Biomaterials. 2006 Nov;27(31):5452-8 [16843524.001]
  • (PMID = 20733505.001).
  • [ISSN] 1536-0210
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / 1R43EB007857; United States / NIBIB NIH HHS / EB / R01 EB002185; United States / NIBIB NIH HHS / EB / R43 EB007857; United States / NIBIB NIH HHS / EB / 2R44EB007857; United States / NIBIB NIH HHS / EB / R44 EB007857; United States / NCI NIH HHS / CA / R44 CA113080; United States / NCI NIH HHS / CA / 2R44CA113080
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ NIHMS387550; NLM/ PMC3426362
  •  go-up   go-down


44. bin Sabir Husin Athar PP, bte Ahmad Norhan N, bin Saim L, bin Md Rose I, bte Ramli R: Metastasis to the sinonasal tract from sigmoid colon adenocarcinoma. Ann Acad Med Singapore; 2008 Sep;37(9):788-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis to the sinonasal tract from sigmoid colon adenocarcinoma.
  • INTRODUCTION: Metastatic adenocarcinoma from the gastrointestinal tract to the sinonasal tract is rare.
  • The histological morphology of this lesion is indistinguishable from the colonic variant of primary sinus adenocarcinoma or intestinal-type adenocarcinoma (ITAC).
  • CLINICAL PICTURE: This is a report of a case of metastatic adenocarcinoma of colorectal origin to the paranasal sinuses in a 52-year-old female who was previously treated for adenocarcinoma of the sigmoid colon.
  • A histologic study of the surgical specimen from the sinonasal cavity demonstrated a tumour identical to the patient's prior primary tumour of the colon.
  • The sinonasal neoplastic tissue showed marked positivity for carcinoembryonic antigen and expressed cytokeratin 20, which differentiates metastatic colonic adenocarcinoma from ITAC.
  • CONCLUSION: Distinguishing metastatic adenocarcinoma from gastrointestinal tract from ITAC can be difficult.
  • [MeSH-major] Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Paranasal Sinus Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18989497.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-20
  •  go-up   go-down


45. Dalzell JR, Samuel LM: The spectrum of 5-fluorouracil cardiotoxicity. Anticancer Drugs; 2009 Jan;20(1):79-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of severe toxicity in a relatively young and fit male patient being treated for metastatic colonic adenocarcinoma displaying characteristics that cannot be explained by either mechanism alone.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Neoplasms / drug therapy. Fluorouracil / adverse effects. Heart Diseases / chemically induced. Liver Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19353811.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Cardiovascular Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 14
  •  go-up   go-down


46. Oikonomou E, Makrodouli E, Evagelidou M, Joyce T, Probert L, Pintzas A: BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. Neoplasia; 2009 Nov;11(11):1116-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells.
  • In colorectal cancer, BRAF and KRAS oncogenes are mutated in about 15% and 35% respectively at approximately the same stage of the adenoma-carcinoma sequence.
  • Since these two mutations rarely coexist, further analysis to dissect their function of transformation in colon cancer is required.
  • Caco-2 human colon adenocarcinoma cells were stably transfected with BRAF(V600E) (Caco-BR cells) or KRAS(G12V) (Caco-K cells) oncogenes.
  • Interestingly, BRAF(WT)gets equally activated by upstream KRAS mutations present in colon adenocarcinoma cells such as DLD-1 and SW620.
  • Taken together, these results suggest that the two oncogenes have different transforming capability in colon cancer, although they both use the mitogen-activated protein (MAP) kinase pathway to carry out their effect.
  • [MeSH-major] Cell Aging / genetics. Cell Transformation, Neoplastic / genetics. Colonic Neoplasms / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins B-raf / genetics. ras Proteins / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1983 Oct 15;32(4):407-12 [6352518.001]
  • [Cites] Nat Cell Biol. 2007 May;9(5):483-5 [17473855.001]
  • [Cites] J Struct Biol. 2007 Jul;159(1):56-70 [17428679.001]
  • [Cites] Mol Cell Biol. 2008 Jan;28(1):511-27 [17967895.001]
  • [Cites] Cancer Lett. 2008 Mar 18;261(2):137-46 [18280030.001]
  • [Cites] Mol Cancer Ther. 2008 Apr;7(4):737-9 [18375819.001]
  • [Cites] Nat Genet. 2008 May;40(5):600-8 [18372904.001]
  • [Cites] Oncogene. 2008 Sep 11;27(40):5315-25 [18521085.001]
  • [Cites] Br J Cancer. 2008 Nov 18;99(10):1607-12 [18941461.001]
  • [Cites] Target Oncol. 2009 Jan;4(1):57-62 [19343302.001]
  • [Cites] J Clin Oncol. 2009 Apr 10;27(11):1814-21 [19273709.001]
  • [Cites] Oncol Rep. 2009 May;21(5):1283-7 [19360305.001]
  • [Cites] Biochem J. 2000 Oct 15;351 Pt 2:289-305 [11023813.001]
  • [Cites] Nature. 2001 Feb 22;409(6823):1067-70 [11234019.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3253-7 [12082642.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Nature. 2002 Aug 29;418(6901):934 [12198537.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1804-11 [12454837.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6997-7000 [12460918.001]
  • [Cites] EMBO J. 2003 May 1;22(9):2036-46 [12727871.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):459-65 [12778136.001]
  • [Cites] Oncogene. 2003 Sep 1;22(37):5876-84 [12947394.001]
  • [Cites] Nat Med. 2003 Oct;9(10):1266-8 [12960962.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(1):465-74 [14673178.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8132-7 [14678966.001]
  • [Cites] Biochem J. 2004 Apr 1;379(Pt 1):209-16 [14715079.001]
  • [Cites] Carcinogenesis. 2004 Apr;25(4):527-33 [14688025.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):303-4 [15093535.001]
  • [Cites] Cell Res. 2004 Aug;14(4):303-14 [15353127.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3950-7 [15459217.001]
  • [Cites] Bioinformatics. 2004 Oct 12;20(15):2471-2 [15073005.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):313-9 [15488754.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4525-30 [7553621.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Cell. 1997 Mar 7;88(5):593-602 [9054499.001]
  • [Cites] FEBS Lett. 1997 Apr 14;406(3):234-42 [9136893.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):5598-611 [9271435.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10330-4 [9294210.001]
  • [Cites] J Clin Invest. 1998 Jan 1;101(1):153-9 [9421477.001]
  • [Cites] J Natl Cancer Inst. 1998 May 6;90(9):675-84 [9586664.001]
  • [Cites] Genes Dev. 1998 Oct 1;12(19):2997-3007 [9765202.001]
  • [Cites] Genes Dev. 1998 Oct 1;12(19):3008-19 [9765203.001]
  • [Cites] Oncogene. 1998 Oct 1;17(13):1731-8 [9796702.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] J Pathol. 1999 Mar;187(4):433-8 [10398103.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Nov;5(11):875-85 [15520807.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):47808-14 [15371409.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4584-94 [15542810.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2465-73 [15781663.001]
  • [Cites] Br J Cancer. 2005 Aug 8;93(3):338-45 [16012517.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Oncogene. 2005 Nov 17;24(51):7630-4 [16007118.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):616-27 [16152623.001]
  • [Cites] Mol Cell. 2005 Dec 22;20(6):963-9 [16364920.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9483-91 [17018604.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):459-72 [17157787.001]
  • [Cites] Mol Cancer. 2007;6:24 [17407548.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • (PMID = 19881948.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2767214
  •  go-up   go-down


47. Fong SF, Dietzsch E, Fong KS, Hollosi P, Asuncion L, He Q, Parker MI, Csiszar K: Lysyl oxidase-like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors. Genes Chromosomes Cancer; 2007 Jul;46(7):644-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lysyl oxidase-like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors.
  • We previously demonstrated the association between increased LOXL2 expression and invasive/metastatic behavior in human breast cancer cells and mouse squamous and spindle cell carcinomas, interaction between LOXL2 and SNAIL in epithelial-mesenchymal transition, and localization of the LOXL2 gene to 8p21.2-21.3, within a minimally deleted region in several cancers, including colon and esophagus.
  • In the present study, we analyzed LOXL2 expression in colon and esophageal tumors, and explored methylation as a regulator of LOXL2 expression.
  • Immunohistochemistry using normal tissues demonstrated intracellular localization of LOXL2 in colonic enteroendocrine cells and esophageal squamous cells at the luminal surface, but not in mitotically active cells.
  • Tissue array analysis of 52 colon adenocarcinomas and 50 esophageal squamous cell carcinomas revealed presence of LOXL2 expression in 83 and 92% of the samples, respectively, and a significant association between increased number of LOXL2-expressing cells and less-differentiated colon carcinomas.
  • Loss of heterozygosity studies, using a microsatellite within intron 4 of the LOXL2 gene, revealed that loss of LOXL2 was unlikely to play a major role in either colon or esophageal tumors.
  • These results suggest that increased LOXL2 expression in colon and esophageal cancer may contribute to tumor progression.
  • [MeSH-major] Amino Acid Oxidoreductases / genetics. Cell Differentiation / genetics. Colonic Neoplasms / enzymology. Esophageal Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17394133.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 76580; United States / NCRR NIH HHS / RR / G12-RR-003061
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 776B62CQ27 / decitabine; EC 1.4.- / Amino Acid Oxidoreductases; EC 1.4.3.- / LOXL2 protein, human; M801H13NRU / Azacitidine
  •  go-up   go-down


48. Ryoichi S, Hiroyuki M, Nobuyuki N, Tomohiro U, Jang KC: Colonic adenocarcinoma in an Indiana pouch successfully treated by endoscopic mucosal resection. Int J Urol; 2007 Jul;14(7):661-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic adenocarcinoma in an Indiana pouch successfully treated by endoscopic mucosal resection.
  • We report the case of a 76-year-old woman who developed a colonic adenocarcinoma and a stone in an Indiana pouch 15 years after the urinary diversion.
  • The colonic adenocarcinoma was treated endoscopically and we were able to preserve the Indiana pouch.
  • To our knowledge, this is the sixth case of colonic adenocarcinoma in an Indiana pouch.
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Colonoscopy. Postoperative Complications / surgery. Urinary Reservoirs, Continent

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645616.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 8
  •  go-up   go-down


49. Sylvestre M, Legault J, Dufour D, Pichette A: Chemical composition and anticancer activity of leaf essential oil of Myrica gale L. Phytomedicine; 2005 Apr;12(4):299-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The anticancer activities of these extracts were assessed against human lung carcinoma cell line A-549 and human colon adenocarcinoma cell line, DLD-1.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15898708.001).
  • [ISSN] 0944-7113
  • [Journal-full-title] Phytomedicine : international journal of phytotherapy and phytopharmacology
  • [ISO-abbreviation] Phytomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Oils
  •  go-up   go-down


50. Solomon DA, Kim JS, Cronin JC, Sibenaller Z, Ryken T, Rosenberg SA, Ressom H, Jean W, Bigner D, Yan H, Samuels Y, Waldman T: Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res; 2008 Dec 15;68(24):10300-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These data implicate PTPRD in the pathogenesis of tumors of neuroectodermal origin and, when taken together with other recent reports of PTPRD mutations in adenocarcinoma of the colon and lung, suggest that PTPRD may be one of a select group of tumor suppressor genes that are inactivated in a wide range of common human tumor types.


51. Chaleoykitti B: Mucinous carcinoma of the colon and rectum in Phramongkutklao Hospital. J Med Assoc Thai; 2006 Jan;89(1):25-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoma of the colon and rectum in Phramongkutklao Hospital.
  • OBJECTIVE: The objective of the present study was to compare the clinicopathological significance between mucinous carcinoma and nonmucinous adenocarcinoma.
  • MATERIAL AND METHOD: Patients with carcinoma of the colon and rectum who had the first operation in the Department of Surgery, Phramongkutklao Hospital between 1999 and 2004 were included in the present study.
  • CONCLUSION: Colorectal mucinous carcinoma had no clinicopathological difference from nonmucinous adenocarcinoma of colon and rectum.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Colonic Neoplasms / pathology. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16583577.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


52. Soga K, Konishi H, Tatsumi N, Konishi C, Nakano K, Wakabayashi N, Mitsufuji S, Kataoka K, Okanoue T, Mukaisho K, Hattori T: Clear cell adenocarcinoma of the colon: a case report and review of literature. World J Gastroenterol; 2008 Feb 21;14(7):1137-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the colon: a case report and review of literature.
  • A primary clear cell adenocarcinoma of the colon is a rare oncologic entity.
  • We herein report a case of such a tumor of the sigmoid colon in a 71-year-old woman who was successfully treated by an endoscopic polypectomy in our hospital.
  • We also reviewed the published reports regarding cases of primary clear cell tumors in the colon.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1993 Jan;15(1):61-4 [8334942.001]
  • [Cites] Tumori. 1992 Jun 30;78(3):219-20 [1440947.001]
  • [Cites] Eur Urol. 1997;31(1):73-80 [9032539.001]
  • [Cites] Int J Urol. 1996 Nov;3(6):501-3 [9170582.001]
  • [Cites] Urology. 1997 Oct;50(4):636-42 [9338750.001]
  • [Cites] J Surg Oncol. 1998 Mar;67(3):182-5 [9530889.001]
  • [Cites] Urology. 1998 Jun;51(6):1057-61 [9609655.001]
  • [Cites] Eur Urol. 1999;35(3):242-8 [10072628.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1593-8 [10193951.001]
  • [Cites] Histopathology. 1999 Mar;34(3):250-6 [10217566.001]
  • [Cites] Surg Today. 1999;29(5):449-52 [10333418.001]
  • [Cites] Cancer. 1964 Feb;17:259-63 [14123687.001]
  • [Cites] Arch Esp Urol. 2000 Jan-Feb;53(1):79-81 [10730432.001]
  • [Cites] World J Surg. 2000 Sep;24(9):1047-51 [11036280.001]
  • [Cites] J Clin Pathol. 2001 Jan;54(1):76-7 [11271795.001]
  • [Cites] Ann Ital Chir. 2000 Nov-Dec;71(6):643-7; discussion 647-8 [11347315.001]
  • [Cites] Urology. 2002 Apr;59(4):615-20 [11927338.001]
  • [Cites] Int J Colorectal Dis. 2004 May;19(3):264-7 [14557891.001]
  • [Cites] Int J Gynecol Cancer. 2004 Mar-Apr;14(2):259-70 [15086725.001]
  • [Cites] Union Med Can. 1976 Sep;105(9):1351-3 [969045.001]
  • [Cites] Obstet Gynecol. 1987 Oct;70(4):573-7 [3627626.001]
  • [Cites] Arch Pathol Lab Med. 1988 Feb;112(2):197-9 [3276291.001]
  • [Cites] Am J Obstet Gynecol. 1990 Jan;162(1):161-3 [2301485.001]
  • [Cites] Gynecol Oncol. 1990 Dec;39(3):314-20 [2258077.001]
  • [Cites] J Clin Pathol. 1995 Dec;48(12):1142-4 [8568005.001]
  • (PMID = 18286700.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 25
  • [Other-IDs] NLM/ PMC2689421
  •  go-up   go-down


53. Kehler T, Curković B: Polymyalgia rheumatica and colon malignacy: case report. Clin Rheumatol; 2006 Sep;25(5):764-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymyalgia rheumatica and colon malignacy: case report.
  • Polymyalgia rheumatica (PMR) is a relatively common disorder in the elderly.
  • We are presenting a patient with PMR and adenocarcinoma of the sygmoid colon and hypothesize a paraneoplastic relationship.
  • [MeSH-major] Adenocarcinoma / complications. Colonic Neoplasms / complications. Polymyalgia Rheumatica / complications

  • MedlinePlus Health Information. consumer health - Polymyalgia Rheumatica.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Geriatr Soc. 2004 Jun;52(6):1028-30 [15161481.001]
  • [Cites] Semin Arthritis Rheum. 2004 Aug;34(1):454-64 [15305244.001]
  • [Cites] Ann Rheum Dis. 1999 May;58(5):303-8 [10225816.001]
  • [Cites] Rheumatology (Oxford). 2003 Feb;42(2):385-7 [12595644.001]
  • [Cites] J Am Geriatr Soc. 2005 Feb;53(2):355-6 [15673369.001]
  • [Cites] Ann Intern Med. 1982 Nov;97(5):672-80 [6982645.001]
  • [Cites] Ann Rheum Dis. 2005 Apr;64(4):626-9 [15769919.001]
  • [Cites] Ann Rheum Dis. 1979 Oct;38(5):434-9 [518143.001]
  • [Cites] Curr Opin Rheumatol. 2001 Jan;13(1):62-6 [11148717.001]
  • [Cites] Arch Intern Med. 1993 Sep 13;153(17):2043-5 [8357289.001]
  • [Cites] Best Pract Res Clin Rheumatol. 2004 Oct;18(5):705-22 [15454128.001]
  • [Cites] Curr Opin Rheumatol. 2003 Jan;15(1):35-43 [12496508.001]
  • [Cites] J Rheumatol. 2005 Jan;32(1):200-1 [15630760.001]
  • [Cites] Ann Rheum Dis. 2003 Dec;62(12):1189-94 [14644857.001]
  • [Cites] Geriatrics. 2004 Nov;59(11):39-43; quiz 44 [15615159.001]
  • [Cites] Clin Rheumatol. 1996 Sep;15(5):486-90 [8894363.001]
  • (PMID = 16249824.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glucocorticoids; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


54. Nicassio F, Bianchi F, Capra M, Vecchi M, Confalonieri S, Bianchi M, Pajalunga D, Crescenzi M, Bonapace IM, Di Fiore PP: A cancer-specific transcriptional signature in human neoplasia. J Clin Invest; 2005 Nov;115(11):3015-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cancer-specific transcriptional signature in human neoplasia.
  • The molecular anatomy of cancer cells is being explored through unbiased approaches aimed at the identification of cancer-specific transcriptional signatures.
  • Furthermore, this overexpression correlated with tumor progression in colon cancer, and 2 of these genes predicted unfavorable prognosis in breast cancer.
  • SKIN was found overexpressed in some primary tumors and tumor cell lines and was amplified in a fraction of colon adenocarcinomas.
  • Thus, SKIN is a candidate oncogene in human cancer.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1986 Apr;83(7):2167-71 [2938185.001]
  • [Cites] EMBO J. 1998 Oct 15;17(20):5987-97 [9774342.001]
  • [Cites] Oncogene. 1988 Feb;2(2):105-12 [2966920.001]
  • [Cites] Nature. 1988 Jul 14;334(6178):124-9 [2968522.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(15):5883-7 [2143024.001]
  • [Cites] Cell. 1990 Aug 24;62(4):659-69 [2143697.001]
  • [Cites] Nature. 1991 Jun 6;351(6326):494-7 [1710781.001]
  • [Cites] Genes Dev. 1992 May;6(5):888-902 [1315706.001]
  • [Cites] Oncogene. 1993 Feb;8(2):267-78 [8381218.001]
  • [Cites] Oncogene. 1993 Mar;8(3):619-24 [8437845.001]
  • [Cites] J Virol. 1993 May;67(5):2456-65 [8386263.001]
  • [Cites] J Cell Physiol. 1995 Jan;162(1):26-35 [7814449.001]
  • [Cites] J Virol. 1995 May;69(5):2962-7 [7707522.001]
  • [Cites] J Biol Chem. 1995 Apr 7;270(14):7791-4 [7713869.001]
  • [Cites] Cell. 1995 Aug 25;82(4):675-84 [7664346.001]
  • [Cites] J Cell Biol. 1996 Feb;132(4):657-66 [8647896.001]
  • [Cites] Mol Cell Biol. 1996 Oct;16(10):5302-12 [8816442.001]
  • [Cites] Cell Growth Differ. 1996 Aug;7(8):1039-50 [8853900.001]
  • [Cites] Mol Cell. 1997 Dec;1(1):35-45 [9659901.001]
  • [Cites] EMBO J. 1998 Aug 3;17(15):4469-77 [9687513.001]
  • [Cites] Exp Cell Res. 2000 Feb 1;254(2):249-56 [10640423.001]
  • [Cites] Genes Dev. 2000 Apr 15;14(8):994-1004 [10783170.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1553-77 [10887150.001]
  • [Cites] Genes Dev. 2001 Feb 1;15(3):267-85 [11159908.001]
  • [Cites] Mamm Genome. 2001 Mar;12(3):192-8 [11252167.001]
  • [Cites] Mol Cell Biol. 2001 Aug;21(15):4985-95 [11438655.001]
  • [Cites] Cell. 2001 Aug 10;106(3):297-307 [11509179.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]
  • [Cites] Oncogene. 2001 Dec 13;20(57):8270-5 [11781841.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1932-41 [11919254.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12963-8 [12297621.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):910-7 [12459729.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Genes Dev. 2003 Feb 1;17(3):336-41 [12569123.001]
  • [Cites] Nature. 2003 Apr 17;422(6933):735-8 [12700765.001]
  • [Cites] Nature. 2003 Jul 10;424(6945):223-8 [12853964.001]
  • [Cites] Mol Cell. 2003 Jul;12(1):255-60 [12887910.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(22):8334-44 [14585990.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):46124-37 [12923195.001]
  • [Cites] Cell. 2004 May 28;117(5):649-62 [15163412.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):539-51 [15193257.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(15):6811-23 [15254247.001]
  • [Cites] Genes Dev. 2004 Jul 15;18(14):1681-94 [15231717.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):949-51 [15286789.001]
  • [Cites] J Cell Biol. 2004 Sep 13;166(6):865-76 [15364961.001]
  • [Cites] Oncogene. 1999 Sep 9;18(36):5054-62 [10490842.001]
  • [Cites] J Cell Biol. 2004 Nov 8;167(3):417-23 [15520231.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):5988-97 [15447982.001]
  • [Cites] EMBO J. 1987 Mar;6(3):605-10 [3034598.001]
  • (PMID = 16224537.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Grant] Italy / Telethon / / GP0293Y01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenovirus E1A Proteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC1253624
  •  go-up   go-down


55. Meyer SE, Waltz SE, Goss KH: The Ron receptor tyrosine kinase is not required for adenoma formation in Apc(Min/+) mice. Mol Carcinog; 2009 Nov;48(11):995-1004
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Ron receptor tyrosine kinase is overexpressed in approximately half of all human colon cancers.
  • Increased Ron expression positively correlates with tumor progression, and reduction of Ron levels in human colon adenocarcinoma cells reverses their tumorigenic properties.
  • Nearly all colon tumors demonstrate loss of the adenomatous polyposis coli (APC) tumor suppressor, an early initiating event, subsequently leading to beta-catenin stabilization.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1999 Nov 1;18(21):5931-42 [10545105.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] Exp Cell Res. 2000 Nov 25;261(1):229-38 [11082293.001]
  • [Cites] Dig Dis Sci. 2001 Feb;46(2):424-9 [11281194.001]
  • [Cites] Nat Genet. 2001 Jun;28(2):155-9 [11381263.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5010-5 [11431334.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5857-68 [11486025.001]
  • [Cites] J Clin Invest. 2001 Aug;108(4):567-76 [11518730.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8357-60 [11731407.001]
  • [Cites] Genome Res. 2002 Jan;12(1):88-97 [11779834.001]
  • [Cites] Cancer Lett. 2002 Sep 8;183(1):31-41 [12049812.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2051-3 [12242442.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38104-10 [12177064.001]
  • [Cites] Hepatology. 2002 Nov;36(5):1053-60 [12395314.001]
  • [Cites] Oncogene. 2003 Jan 16;22(2):186-97 [12527888.001]
  • [Cites] Curr Cancer Drug Targets. 2003 Feb;3(1):31-40 [12570659.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):762-77 [12612914.001]
  • [Cites] Carcinogenesis. 2003 Aug;24(8):1291-300 [12807733.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3694-700 [15150130.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] J Cell Biol. 1992 Mar;116(6):1517-26 [1541640.001]
  • [Cites] Science. 1992 May 1;256(5057):668-70 [1350108.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] Oncogene. 1999 May 6;18(18):2883-91 [10362259.001]
  • [Cites] Int J Oncol. 1999 Oct;15(4):709-14 [10493952.001]
  • [Cites] Oncogene. 2004 Nov 4;23(52):8464-74 [15378025.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):27-36 [15447977.001]
  • [Cites] Virchows Arch. 1997 Sep;431(3):167-72 [9334837.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1087-9 [9515784.001]
  • [Cites] Carcinogenesis. 1998 Apr;19(4):543-9 [9600336.001]
  • [Cites] Exp Lung Res. 1998 Jul-Aug;24(4):437-53 [9659576.001]
  • [Cites] Genes Funct. 1997 Feb;1(1):69-83 [9680329.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Int J Cancer. 1998 Nov 23;78(5):629-35 [9808534.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1399-405 [10188882.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):479-88 [15531916.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1285-93 [15735014.001]
  • [Cites] Ann Surg Oncol. 2005 Apr;12(4):273-81 [15827676.001]
  • [Cites] Acta Pharmacol Sin. 2006 Jun;27(6):641-50 [16723080.001]
  • [Cites] Cancer Sci. 2006 Aug;97(8):710-5 [16863504.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8430-8 [16951153.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9162-70 [16982759.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11967-74 [17178895.001]
  • [Cites] Genetics. 2007 Jun;176(2):1237-44 [17435219.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6075-82 [17616662.001]
  • [Cites] Future Oncol. 2007 Aug;3(4):441-8 [17661719.001]
  • [Cites] J Pathol. 2007 Dec;213(4):402-11 [17955509.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6680-7 [18701492.001]
  • [Cites] Oncogene. 1993 May;8(5):1195-202 [8386824.001]
  • [Cites] Hum Mol Genet. 1992 Sep;1(6):387-90 [1338760.001]
  • [Cites] J Cell Biol. 1993 Nov;123(4):877-93 [8227147.001]
  • [Cites] Biochim Biophys Acta. 1993 Dec 23;1155(3):357-71 [8268192.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5953-8 [7954428.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1061-4 [7576992.001]
  • [Cites] Acta Gastroenterol Belg. 1995 Sep-Dec;58(5-6):433-51 [8776001.001]
  • [Cites] Gastroenterology. 1996 Oct;111(4):1134-40 [8831610.001]
  • [Cites] EMBO J. 1996 Nov 1;15(21):5866-75 [8918464.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1402-7 [9037065.001]
  • [Cites] Scand J Gastroenterol. 2000 May;35(5):534-9 [10868458.001]
  • (PMID = 19452510.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA059268; United States / NCI NIH HHS / CA / R01 CA125379; United States / NCI NIH HHS / CA / CA 100002; United States / NCI NIH HHS / CA / R01 CA100002; United States / NCI NIH HHS / CA / T32 CA 59268
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.7.1.- / RON protein; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ NIHMS600186; NLM/ PMC4102426
  •  go-up   go-down


56. Frade RF, Candeias NR, Duarte CM, André V, Duarte MT, Gois PM, Afonso CA: New dirhodium complex with activity towards colorectal cancer. Bioorg Med Chem Lett; 2010 Jun 1;20(11):3413-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New dirhodium complex with activity towards colorectal cancer.
  • A novel dirhodium complex (Rh(2)(L-PheAla)(2)(OAc)(2) is reported with strong activity towards human colon adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Rhodium / pharmacology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. RHODIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20434912.001).
  • [ISSN] 1464-3405
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; DMK383DSAC / Rhodium; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


57. Ferreira F, Lopes S, Macedo G: Colon cancer after infliximab therapy for Crohn's disease. BioDrugs; 2010 Dec 14;24 Suppl 1:18-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon cancer after infliximab therapy for Crohn's disease.
  • Therapy with infliximab is generally well tolerated but there are concerns about its effects on the incidence of cancer.
  • This case report refers to a 47-year-old patient with long-standing Crohn's disease, without a family history of colorectal cancer, who had a previous diagnosis of low-grade dysplasia that was not confirmed in subsequent studies, and was diagnosed with adenocarcinoma of the colon with peritoneal invasion after the fourth infusion of infliximab.
  • [MeSH-major] Adenocarcinoma / etiology. Anti-Inflammatory Agents / adverse effects. Antibodies, Monoclonal / adverse effects. Colonic Neoplasms / etiology. Crohn Disease / drug therapy
  • [MeSH-minor] Colon. Humans. Infliximab. Male. Middle Aged

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • Hazardous Substances Data Bank. Infliximab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21175230.001).
  • [ISSN] 1179-190X
  • [Journal-full-title] BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • [ISO-abbreviation] BioDrugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; B72HH48FLU / Infliximab
  •  go-up   go-down


58. Dimitroulopoulos DA, Arnogiannaki NA, Korkolis DP, Xinopoulos DN, Paraskevas ET, Fotopoulou AP: Synchronous occurrence of colorectal adenocarcinoma and colonic gastrointestinal stromal tumor. South Med J; 2009 Feb;102(2):221-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous occurrence of colorectal adenocarcinoma and colonic gastrointestinal stromal tumor.
  • [MeSH-major] Adenocarcinoma / pathology. Colon / pathology. Colorectal Neoplasms / pathology. Gastrointestinal Stromal Tumors / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19139690.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


59. Szajda SD, Snarska J, Puchalski Z, Zwierz K: Lysosomal exoglycosidases in serum and urine of patients with colon adenocarcinoma. Hepatogastroenterology; 2008 May-Jun;55(84):921-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lysosomal exoglycosidases in serum and urine of patients with colon adenocarcinoma.
  • 3.2.1.24) in blood serum and urine in diagnostics of colon adenocarcinoma.
  • METHODOLOGY: The activity of lysosomal exoglycosidases was determined by the method of Marciniak et al. adapted to serum and urine of patients with adenocarcinoma of the colon.
  • RESULTS: A significant increase in concentration of the activity of HEX, GAL and FUC was found in blood serum, as well as HEX and GAL in urine, of patients with colon adenocarcinoma, in comparison with healthy people.
  • With the method of Marciniak et al. for determination the activity of HEX, GAL and FUC in blood serum as well as HEX and GAL in urine, the cases of colon adenocarcinoma were significantly differentiated from healthy people.
  • CONCLUSIONS: The high diagnostic value, sensitivity and specificity of the method of Marciniak et al., suggests the possibility of its use for determination of the activity of HEX, FUC and GAL in blood serum as well as HEX and GAL in urine, in the diagnostics of colon adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / enzymology. Biomarkers, Tumor / metabolism. Colonic Neoplasms / diagnosis. Colonic Neoplasms / enzymology. Glycoside Hydrolases / metabolism. Lysosomes / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705298.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.2.1.- / Glycoside Hydrolases; EC 3.2.1.23 / beta-Galactosidase; EC 3.2.1.24 / alpha-Mannosidase; EC 3.2.1.51 / alpha-L-Fucosidase; EC 3.2.1.52 / beta-N-Acetylhexosaminidases
  •  go-up   go-down


60. Taweevisit M: The association of stromal mast cell response and tumor cell differentiation in colorectal cancer. J Med Assoc Thai; 2006 Sep;89 Suppl 3:S69-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association of stromal mast cell response and tumor cell differentiation in colorectal cancer.
  • Mast cells, a type of inflammatory cells, may play a role in colonic cancer pathogenesis.
  • OBJECTIVE: To evaluate the relation between mast cell number and biology of colorectal adenocarcinoma.
  • MATERIAL AND METHOD: The author collected 162 cases, diagnosed as primary adenocarcinoma of the colon at the King Chulalongkorn Memorial Hospital, between 2002 and 2003, for evaluating the role of mast cells in colorectal cancers.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Mast Cells / pathology. Stromal Cells / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17718271.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


61. Gravante G, Delogu D, Venditti D: Colosigmoid adenocarcinoma anastomotic recurrence seeding into a transsphincteric fistula-in-ano: a clinical report and literature review. Surg Laparosc Endosc Percutan Tech; 2008 Aug;18(4):407-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colosigmoid adenocarcinoma anastomotic recurrence seeding into a transsphincteric fistula-in-ano: a clinical report and literature review.
  • We describe the case of a left colon adenocarcinoma anastomotic recurrence that metastasized to a benign transsphincteric fistula-in-ano, presumably through the implantation of viable malignant cells shed from the secondary tumor, and discuss the implications of these findings in colorectal cancer surgery.
  • [MeSH-major] Adenocarcinoma / secondary. Neoplasm Recurrence, Local / pathology. Neoplasm Seeding. Rectal Fistula / pathology. Rectal Neoplasms / secondary. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716545.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


62. Sieren LM, Collins JN, Weireter LJ, Britt RC, Reed SF, Novosel TJ, Britt LD: The incidence of benign and malignant neoplasia presenting as acute appendicitis. Am Surg; 2010 Aug;76(8):808-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Final pathology revealed four colonic adenocarcinoma; three mucinous tumors; one carcinoid; one endometrioma; and one patient had a combination of a mucinous cystadenoma, a carcinoid tumor, and endometriosis of the appendix.
  • Colonic and appendiceal neoplasia are not unusual etiologies of appendicitis.

  • MedlinePlus Health Information. consumer health - Appendicitis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20726408.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Richter SN, Cartei G, Nadai M, Trestin A, Barzon L, Palumbo M, Palù G: In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancer. Ann Oncol; 2006 May;17 Suppl 5:v20-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancer.
  • A real-time RT-PCR method was designed to quantify topoisomerase expression after treatment with gemcitabine (GEM) in two human colon adenocarcinoma cell lines.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807457.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Topoisomerase Inhibitors; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 5.99.1.- / DNA Topoisomerases
  •  go-up   go-down


64. Yokomizo A, Moriwaki M: Effects of uptake of flavonoids on oxidative stress induced by hydrogen peroxide in human intestinal Caco-2 cells. Biosci Biotechnol Biochem; 2006 Jun;70(6):1317-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The relation between the uptake of flavonoids and the response of human colon adenocarcinoma Caco-2 cells exposed to oxidative stress induced by hydrogen peroxide (H(2)O(2)) was examined.

  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16794309.001).
  • [ISSN] 0916-8451
  • [Journal-full-title] Bioscience, biotechnology, and biochemistry
  • [ISO-abbreviation] Biosci. Biotechnol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Culture Media; 0 / Flavonoids; 0 / Free Radicals; 0 / Reactive Oxygen Species; BBX060AN9V / Hydrogen Peroxide
  •  go-up   go-down


65. Hassani M, Cai W, Holley DC, Lineswala JP, Maharjan BR, Ebrahimian GR, Seradj H, Stocksdale MG, Mohammadi F, Marvin CC, Gerdes JM, Beall HD, Behforouz M: Novel lavendamycin analogues as antitumor agents: synthesis, in vitro cytotoxicity, structure-metabolism, and computational molecular modeling studies with NAD(P)H:quinone oxidoreductase 1. J Med Chem; 2005 Dec 1;48(24):7733-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytotoxicity toward human colon adenocarcinoma cells was determined for the lavendamycins.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16302813.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA74245; United States / NCRR NIH HHS / RR / P20 RR15583; United States / NCI NIH HHS / CA / R15 CA788232
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / decarboxy-2'-(hydroxymethyl)-demethyllavendamycin; 261Q3JB310 / Streptonigrin; 81645-09-2 / lavendamycin; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone)
  •  go-up   go-down


66. Liang L, Wang XY, Zhang XH, Zhao WC, Deng HZ: [Screening on alkaloid of Sophora alopecuraides against adenocarcinoma of colon cell line SW620 in vitro]. Zhong Yao Cai; 2008 Jun;31(6):866-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Screening on alkaloid of Sophora alopecuraides against adenocarcinoma of colon cell line SW620 in vitro].
  • OBJECTIVE: To test 5 kinds of alkaloid of Sophora alopecuraides L., the effects of TBSA, MT, OMT, SC, SRI against adenocarcinoma of colon cell line SW620.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / ultrastructure. Cell Line, Tumor. Colorectal Neoplasms / pathology. Colorectal Neoplasms / ultrastructure. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Flow Cytometry. Humans. Quinolizines / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18998571.001).
  • [ISSN] 1001-4454
  • [Journal-full-title] Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials
  • [ISO-abbreviation] Zhong Yao Cai
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Antineoplastic Agents, Phytogenic; 0 / Quinolizines; 519-02-8 / matrine
  •  go-up   go-down


67. Hare HH, Mahendraker N, Sarwate S, Tangella K: Muir-Torre syndrome: a rare but important disorder. Cutis; 2008 Oct;82(4):252-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Muir-Torre syndrome: a rare but important disorder.
  • Muir-Torre syndrome (MTS) is a rare disorder characterized by the presence of at least one sebaceous gland neoplasm and at least one visceral malignancy.
  • Muir-Torre syndrome is an autosomal dominant disorder; however, sporadic cases are known to develop.
  • It often is associated with germ-line mutations in the mutS homolog 2, colon cancer, nonpolyposis type 1 (Escherichia coli) gene, MSH2, and the mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) gene, MLH1 (similar to hereditary nonpolyposis colon cancer [HNPCC]).
  • We report 2 patients with MTS who developed colon adenocarcinomas in conjunction with sebaceous carcinomas.

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055168.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Greenblatt DY, Weber SM, O'Connor ES, LoConte NK, Liou JI, Smith MA: Readmission after colectomy for cancer predicts one-year mortality. Ann Surg; 2010 Apr;251(4):659-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Readmission after colectomy for cancer predicts one-year mortality.
  • We sought to determine the rate and predictors of readmission after colectomy for cancer, as well as the association between readmission and mortality.
  • METHODS: Medicare beneficiaries who underwent colectomy for stage I to III colon adenocarcinoma from 1992 to 2002 were identified from the Surveillance, Epidemiology, and End Results-Medicare database.
  • This difference in mortality was significant for all stages of cancer.
  • CONCLUSIONS: Early readmission after colectomy for cancer is common and due in part to modifiable factors.
  • Early readmission is therefore an important quality-of-care indicator for colon cancer surgery.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 2000 Apr 24;160(8):1074-81 [10789599.001]
  • [Cites] N Engl J Med. 2009 Apr 2;360(14):1418-28 [19339721.001]
  • [Cites] Health Care Financ Rev. 2000 Spring;21(3):7-28 [11481769.001]
  • [Cites] Dis Colon Rectum. 2001 Jul;44(7):942-6 [11496073.001]
  • [Cites] Br J Surg. 2001 Nov;88(11):1533-8 [11683754.001]
  • [Cites] Ann Thorac Surg. 2001 Dec;72(6):1855-9; discussion 1859-60 [11789760.001]
  • [Cites] J Am Geriatr Soc. 2001 Nov;49(11):1561-4 [11890600.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-62-8 [12187170.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):503-9 [12682545.001]
  • [Cites] Hepatogastroenterology. 2003 Mar-Apr;50(50):432-7 [12749241.001]
  • [Cites] J Surg Oncol. 2003 Jun;83(2):68-78; discussion 78-9 [12772198.001]
  • [Cites] Dis Colon Rectum. 2003 Jul;46(7):851-9 [12847356.001]
  • [Cites] Ann Surg. 2003 Aug;238(2):161-7 [12894006.001]
  • [Cites] JAMA. 2003 Aug 13;290(6):773-80 [12915430.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1112-7 [14597452.001]
  • [Cites] Br J Surg. 2003 Dec;90(12):1497-504 [14648727.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):271-7; discussion 277-8 [14991487.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):877-83 [15194068.001]
  • [Cites] J Am Coll Surg. 2004 Nov;199(5):675-9 [15501105.001]
  • [Cites] Br J Prev Soc Med. 1965 Oct;19(4):182-91 [5845379.001]
  • [Cites] Am J Med. 1991 Jun;90(6):667-74 [2042681.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • [Cites] Conn Med. 1995 May;59(5):263-70 [7600797.001]
  • [Cites] Health Serv Res. 1995 Aug;30(3):489-506 [7649753.001]
  • [Cites] J Qual Clin Pract. 1995 Dec;15(4):211-20 [8719060.001]
  • [Cites] Med Care. 1997 Oct;35(10):1044-59 [9338530.001]
  • [Cites] J Am Coll Surg. 1998 May;186(5):501-6 [9583689.001]
  • [Cites] Ann Surg. 2005 Mar;241(3):416-23 [15729063.001]
  • [Cites] Surg Endosc. 2004 Oct;18(10):1463-8 [15791370.001]
  • [Cites] Dis Colon Rectum. 1999 Nov;42(11):1381-7 [10566524.001]
  • [Cites] J Epidemiol Community Health. 2005 Jun;59(6):506-11 [15911648.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):629-39 [15983985.001]
  • [Cites] Br J Surg. 2005 Nov;92(11):1354-62 [16237744.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1243-52; discussion 1252-3 [17114011.001]
  • [Cites] Ann Surg. 2007 Jan;245(1):73-9 [17197968.001]
  • [Cites] Arch Intern Med. 2007 Feb 12;167(3):258-64 [17296881.001]
  • [Cites] Am J Manag Care. 2007 Mar;13(3):157-64 [17335359.001]
  • [Cites] J Am Geriatr Soc. 2007 Mar;55(3):365-73 [17341238.001]
  • [Cites] Curr Probl Cancer. 2007 May-Jun;31(3):123-33 [17543944.001]
  • [Cites] Br J Surg. 2007 Jul;94(7):890-3 [17330930.001]
  • [Cites] Dis Colon Rectum. 2007 Sep;50(9):1316-23 [17665252.001]
  • [Cites] Cancer Biomark. 2007;3(6):301-13 [18048968.001]
  • [Cites] World J Surg. 2007 Dec;31(12):2430-5 [18246608.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):900-8 [18181101.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):51-7 [10862195.001]
  • (PMID = 20224370.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N02-PC-15105; United States / PHS HHS / / U55/CCR921930 - 02; None / None / / UL1 RR025011-01; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCRR NIH HHS / RR / UL1 RR025011-01; United States / NCI NIH HHS / CA / P30 CA014520-34; United States / NCI NIH HHS / CA / P30 CA014520; United States / NCI NIH HHS / PC / N02 PC015105; United States / NCRR NIH HHS / RR / UL1 RR025011; United States / NCRR NIH HHS / RR / 1UL1RR025011; None / None / / P30 CA014520-34; United States / NCI NIH HHS / CA / N01PC35136; United States / NCI NIH HHS / CA / N01PC35139; United States / NCI NIH HHS / PC / N01-PC-35136
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS230999; NLM/ PMC2951007
  •  go-up   go-down


69. Gönen M, Schrag D, Weiser MR: Nodal staging score: a tool to assess adequate staging of node-negative colon cancer. J Clin Oncol; 2009 Dec 20;27(36):6166-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodal staging score: a tool to assess adequate staging of node-negative colon cancer.
  • PURPOSE: Adequate nodal staging of colon cancer has been defined as pathologic examination of at least 12 lymph nodes.
  • PATIENTS AND METHODS: Patients with stage I-III adenocarcinoma of the colon between 1994 and 2005 and had at least one lymph node pathologically examined were identified from the Surveillance, Epidemiology and End Results (SEER) database (n = 131,953).
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Lymph Nodes / pathology. Models, Statistical

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]
  • [Cites] Colorectal Dis. 2010 Jan;12(1):44-7 [19438890.001]
  • [Cites] World J Surg. 2002 Mar;26(3):384-9 [11865379.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):458-63 [11923600.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):213-8 [12679304.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] Ann Surg Oncol. 2003 Oct;10(8):903-9 [14527909.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):624-8; discussion 628-30 [15383790.001]
  • [Cites] J Ky Med Assoc. 2004 Aug;102(8):345-7 [15384384.001]
  • [Cites] Am J Clin Pathol. 1996 Aug;106(2):209-16 [8712176.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1829-37 [8859199.001]
  • [Cites] Am J Clin Pathol. 1997 Apr;107(4):494; author reply 494-5 [9124219.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 [15687365.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8671-8 [16314627.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3570-5 [16877723.001]
  • [Cites] Ann Surg. 2006 Oct;244(4):602-10 [16998369.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):414-5 [17374823.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]
  • [Cites] JAMA. 2007 Nov 14;298(18):2149-54 [18000198.001]
  • [Cites] JAMA. 2007 Nov 14;298(18):2194-5 [18000205.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2020-9 [18083404.001]
  • [Cites] JAMA. 2008 Feb 27;299(8):896-7; author reply 897-8 [18314429.001]
  • [Cites] J Natl Cancer Inst. 2008 Sep 17;100(18):1310-7 [18780863.001]
  • [Cites] Int J Colorectal Dis. 2009 Mar;24(3):283-8 [18716784.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):179-89 [11812939.001]
  • (PMID = 19901106.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3651597
  •  go-up   go-down


70. Spiegel A, Hundley TR, Chen J, Gao J, Ouyang N, Liu X, Go MF, Tsioulias GJ, Kashfi K, Rigas B: NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells. Biochem Pharmacol; 2005 Oct 1;70(7):993-1000
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells.
  • Nitric oxide-releasing aspirin (NO-ASA) is emerging as a potentially important chemopreventive agent against colon cancer.
  • We examined in HT-29 human colon adenocarcinoma cells the effect of NO-ASA on the inducible form of nitric oxide synthase (NOS2), an enzyme implicated in colon carcinogenesis.
  • These findings indicate that NO-ASA profoundly inhibits both the expression and enzymatic activity of NOS2 and suggest that these effects may represent an important mechanism for the colon cancer chemopreventive effect of NO-ASA.
  • [MeSH-major] Adenocarcinoma / enzymology. Aspirin / pharmacology. Colonic Neoplasms / enzymology. Nitric Oxide Donors / pharmacology. Nitric Oxide Synthase / antagonists & inhibitors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16105666.001).
  • [ISSN] 0006-2952
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA92423; United States / NCI NIH HHS / CA / R01-CA92423-S2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Nitric Oxide Donors; 0 / RNA, Messenger; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II; R16CO5Y76E / Aspirin
  •  go-up   go-down


71. Jones J, Bentas W, Blaheta RA, Makarevic J, Hudak L, Wedel S, Probst M, Jonas D, Juengel E: Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid. Int J Mol Med; 2008 Sep;22(3):293-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid.
  • The effects of the HDAC inhibitor valproic acid (VPA) were tested in vitro on preclinical colon and pancreatic cancer models.
  • Human colon adenocarcinoma HT-29 and pancreatic carcinoma DanG cells were treated with 1 mM VPA for different time periods during cell proliferation MTT assays, and to evaluate the tumor cell adhesion to endothelial cell monolayers.
  • Further study is required to elucidate the molecular background of the post-transcriptional modifications of VPA in order to exploit the potential of this agent in the treatment of colon and pancreatic cancer.
  • [MeSH-major] Colonic Neoplasms / enzymology. Colonic Neoplasms / pathology. Enzyme Inhibitors / pharmacology. Histone Deacetylase Inhibitors. Pancreatic Neoplasms / enzymology. Pancreatic Neoplasms / pathology. Valproic Acid / pharmacology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698487.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Integrins; 0 / RNA, Messenger; 614OI1Z5WI / Valproic Acid; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


72. Liu L, Sun H, Valji WY, Pang KS: Transporters, enzymes, and enalapril removal in a rat (CC531-induced) liver metastatic model. Am J Physiol Gastrointest Liver Physiol; 2007 Nov;293(5):G1078-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Temporal changes in physiological spaces, protein expression of transporters and enzymes, and enalapril removal were appraised in the metastatic liver tumor model developed from male Wag/Rij rats after the intraportal injection of CC531 colon adenocarcinoma cells; sham-operated preparations received PBS.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17855765.001).
  • [ISSN] 0193-1857
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzymes; 0 / Neoplasm Proteins; 69PN84IO1A / Enalapril
  •  go-up   go-down


73. Patterson-Kane JC, Redrobe SP: Colonic adenocarcinoma in a leopard gecko (Eublepharis macularius). Vet Rec; 2005 Sep 3;157(10):294-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic adenocarcinoma in a leopard gecko (Eublepharis macularius).
  • [MeSH-major] Adenocarcinoma / veterinary. Colonic Neoplasms / veterinary. Lizards

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16157574.001).
  • [ISSN] 0042-4900
  • [Journal-full-title] The Veterinary record
  • [ISO-abbreviation] Vet. Rec.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


74. Ziółkowska E, Biedka M, Zyromska A, Makarewicz R: Psoriasis exacerbation after hormonotherapy in prostate cancer patient-Case report. Rep Pract Oncol Radiother; 2010;15(4):103-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psoriasis exacerbation after hormonotherapy in prostate cancer patient-Case report.
  • Psoriasis, as the most common inflammatory skin disorder, affects about 2-3% of the world's population.
  • Many non-dermatological conditions have been linked with psoriasis, including cardiovascular diseases, depression, inflammatory bowel disorders, and some cancers, i.e. lung, colon and kidney cancers.
  • A 57-year-old Caucasian man was admitted for curative radiation therapy of adenocarcinoma of the prostate after 3 months of initial hormonal therapy.
  • To our best knowledge hormone therapy (androgen deprivation) of prostate cancer patients has not been reported as an aggravating factor.
  • Thus, the aim of our work is to present the case of a prostate cancer patient who experienced psoriasis exacerbation after implementation of hormonal blockade as a neoadjuvant oncological treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24376933.001).
  • [ISSN] 1507-1367
  • [Journal-full-title] Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology
  • [ISO-abbreviation] Rep Pract Oncol Radiother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC3863271
  • [Keywords] NOTNLM ; Hormonotherapy / Prostate cancer / Psoriasis
  •  go-up   go-down


75. Briviba K, Bornemann R, Lemmer U: Visualization of astaxanthin localization in HT29 human colon adenocarcinoma cells by combined confocal resonance Raman and fluorescence microspectroscopy. Mol Nutr Food Res; 2006 Nov;50(11):991-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Visualization of astaxanthin localization in HT29 human colon adenocarcinoma cells by combined confocal resonance Raman and fluorescence microspectroscopy.
  • We show that astaxanthin delivered with tetrahydrofuran is effectively taken up by cultured colon adenocarcinoma cells and is localized mostly in the cytoplasm as detected by confocal resonance Raman and broad-band fluorescence microspectroscopy image analysis.

  • Hazardous Substances Data Bank. ASTAXANTHINE .
  • Hazardous Substances Data Bank. BETA-CAROTENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17039456.001).
  • [ISSN] 1613-4125
  • [Journal-full-title] Molecular nutrition & food research
  • [ISO-abbreviation] Mol Nutr Food Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Xanthophylls; 01YAE03M7J / beta Carotene; 8XPW32PR7I / astaxanthine
  •  go-up   go-down


76. Bommareddy A, Zhang XY, Kaushik RS, Dwivedi C: Effects of components present in flaxseed on human colon adenocarcinoma Caco-2 cells: Possible mechanisms of flaxseed on colon cancer development in animals. Drug Discov Ther; 2010 Jun;4(3):184-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of components present in flaxseed on human colon adenocarcinoma Caco-2 cells: Possible mechanisms of flaxseed on colon cancer development in animals.
  • Previous studies from our laboratory have shown chemopreventive effects of dietary flaxseed on azoxymethane-induced colon tumor development in male Fischer rats and Apc(Min) mice.
  • Accordingly, the objective of this investigation was to study the effects of mammalian lignans (enterodiol and enterolactone) and ω-3 polyunsaturated fatty acid α-linolenic acid, principal active components in flaxseed on cell proliferation and apoptosis in human colon adenocarcinoma Caco-2 cells, thus elucidating possible mechanism of action.
  • Therefore, dietary flaxseed containing α-linolenic acid and lignans causes a decrease in cell proliferation and an increase in apoptosis resulting in the effective chemoprevention for intestinal and colon tumor development.
  • [MeSH-minor] Adenocarcinoma. Animals. Colonic Neoplasms. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22491182.001).
  • [ISSN] 1881-7831
  • [Journal-full-title] Drug discoveries & therapeutics
  • [ISO-abbreviation] Drug Discov Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


77. Facchini G, Fiore F, Caraglia M, D'Angelo R, Nasti G, Caponigro F, Formato R, Budillon A, Iaffaioli RV: A liver angioma colonized by colon cancer cells in a patient with two primitive localizations by colon adenocarcinoma: biologic, diagnostic and therapeutic implications. Ann Oncol; 2005 Dec;16(12):1980-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A liver angioma colonized by colon cancer cells in a patient with two primitive localizations by colon adenocarcinoma: biologic, diagnostic and therapeutic implications.

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Angioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033872.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


78. Shen WW, Wu J, Cai L, Liu BY, Gao Y, Chen GQ, Fu GH: Expression of anion exchanger 1 sequestrates p16 in the cytoplasm in gastric and colonic adenocarcinoma. Neoplasia; 2007 Oct;9(10):812-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of anion exchanger 1 sequestrates p16 in the cytoplasm in gastric and colonic adenocarcinoma.
  • In this article, we show an unexpected expression of anion exchanger 1 (AE1) in the cytoplasm in poorly and moderately differentiated gastric and colonic adenocarcinoma cells and in its interaction with p16, thereby sequestrating the protein in the cytoplasm.
  • By analyzing tissue samples obtained from patients with gastric and colonic cancers, we found that 83.33% of gastric cancers and 56.52% of colonic cancers coexpressed AE1 and p16 in the cytoplasm.
  • We conclude that AE1 plays a crucial role in the pathogenesis of gastric and colonic adenocarcinoma and that p16 dysfunction is a novel pathway of carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Anion Exchange Protein 1, Erythrocyte / biosynthesis. Colonic Neoplasms / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2000 Sep 18;150(6):1467-78 [10995450.001]
  • [Cites] Oncogene. 2006 Jul 6;25(29):4116-21 [16491118.001]
  • [Cites] JOP. 2001 Jul;2(4 Suppl):171-5 [11875255.001]
  • [Cites] J Nephrol. 2002 Mar-Apr;15 Suppl 5:S41-53 [12027221.001]
  • [Cites] Exp Hematol. 2003 May;31(5):355-62 [12763133.001]
  • [Cites] Cancer Cell. 2004 Feb;5(2):121-5 [14998488.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):11-27 [15000146.001]
  • [Cites] Biotech Histochem. 2004 Feb;79(1):5-10 [15223748.001]
  • [Cites] Biochem J. 1988 Feb 15;250(1):1-8 [2965576.001]
  • [Cites] J Biol Chem. 1990 Jan 5;265(1):462-71 [2294114.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5278-82 [2371270.001]
  • [Cites] Cancer Res. 1991 Nov 1;51(21):5800-5 [1933850.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3099-102 [1591722.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):704-7 [8259215.001]
  • [Cites] Am J Physiol. 1993 Dec;265(6 Pt 2):F813-21 [7506871.001]
  • [Cites] Science. 1994 Apr 15;264(5157):436-40 [8153634.001]
  • [Cites] J Biol Chem. 1994 Dec 23;269(51):32201-8 [7798219.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2503-6 [7780957.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1197-206 [9508208.001]
  • [Cites] Nature. 1998 Mar 26;392(6674):402-5 [9537325.001]
  • [Cites] Br J Cancer. 1998 Dec;78(12):1661-8 [9862580.001]
  • [Cites] EMBO J. 1999 Apr 15;18(8):2106-18 [10205165.001]
  • [Cites] Biochem Cell Biol. 1998;76(5):709-13 [10353702.001]
  • [Cites] Int J Oncol. 2005 May;26(5):1217-26 [15809712.001]
  • [Cites] FEBS Lett. 2005 Apr 11;579(10):2105-10 [15811326.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2787-95 [15838515.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1696-716 [15887160.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2005 Sep;14(5):495-501 [16046910.001]
  • [Cites] Exp Physiol. 2006 Jan;91(1):153-61 [16239253.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2129-37 [16489013.001]
  • [Cites] Neoplasia. 2006 Jan;8(1):46-51 [16533425.001]
  • [Cites] Neoplasia. 2006 Jun;8(6):429-36 [16820088.001]
  • [Cites] Ann N Y Acad Sci. 2000;915:81-91 [11193604.001]
  • (PMID = 17971901.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Anion Exchange Protein 1, Erythrocyte; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ PMC2040208
  • [Keywords] NOTNLM ; Anion exchanger 1 / colonic adenocarcinoma / gastric adenocarcinoma / p16 / siRNA
  •  go-up   go-down


79. Rao CV, Steele VE, Swamy MV, Patlolla JM, Guruswamy S, Kopelovich L: Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. Cancer Res; 2009 Oct 15;69(20):8175-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats.
  • Tumor suppressor p53 plays a major role in colorectal cancer development.
  • The present study explores the effects of p53-modulating agent CP-31398 alone and combined with celecoxib on azoxymethane-induced aberrant crypt foci (ACF) and colon adenocarcinomas in F344 rats.
  • ACF and colon adenocarcinomas were determined at 8 and 48 weeks after azoxymethane treatment, respectively.
  • Dietary CP-31398 was shown to suppress mean colonic total ACF by 43% and multicrypt ACF by 63%; dietary CP-31398 at 150 and 300 ppm suppressed adenocarcinoma incidence by 30.4% (P < 0.02) and 44% (P < 0.005), respectively, and adenocarcinoma multiplicity by 51% (P < 0.005) and 65% (P < 0.0001), respectively.
  • Dietary celecoxib suppressed colon adenocarcinoma incidence (60%; P < 0.0003) and multiplicity (70%; P < 0.0001).
  • Importantly, combination of low-dose CP-31398 and celecoxib suppressed colon adenocarcinoma incidence by 78% and multiplicity by 90%.
  • Rats that were fed the high-dose CP-31398 or a combination of low-dose CP-31398 and celecoxib showed considerable enhancement of p53 and p21(WAF1/CIP) expression, apoptosis, and reduced tumor cell proliferation in colonic tumors.
  • These observations show, for the first time, that CP-31398 possesses significant dose-dependent chemopreventive activity in a well-established colon cancer model and that a combination of low-dose CP-31398 and celecoxib significantly enhanced colon cancer chemopreventive efficacy.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1995 Jan 15;55(2):259-66 [7812955.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Apr;2(4):310-21 [19336730.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1033-8 [7576987.001]
  • [Cites] Oncogene. 1996 Dec 5;13(11):2477-82 [8957091.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):761, 763 [9126728.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):409-12 [9458081.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] Curr Gastroenterol Rep. 2005 Oct;7(5):389-95 [16168238.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4542-6 [16618783.001]
  • [Cites] Mol Cancer Ther. 2006 Jun;5(6):1530-8 [16818512.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7370-7 [16849589.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11003-8 [16835297.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):661-5 [17251932.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):656-60 [17251933.001]
  • [Cites] J Am Chem Soc. 2007 Mar 7;129(9):2456-7 [17284038.001]
  • [Cites] Cell. 2007 Mar 9;128(5):837-40 [17350571.001]
  • [Cites] J Clin Invest. 2007 Dec;117(12):3753-64 [18060030.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7670-5 [18794156.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Jan;2(1):52-9 [19139018.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2009;49:265-90 [18851701.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Apr;2(4):285-7 [19336723.001]
  • [Cites] Science. 1999 Dec 24;286(5449):2507-10 [10617466.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):293-7 [10667579.001]
  • [Cites] Oncogene. 2000 Mar 2;19(10):1245-56 [10713666.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9215-20 [10908664.001]
  • [Cites] Cell. 2000 Nov 22;103(5):691-4 [11114324.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3647-52 [11325834.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):165-70 [11782374.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2002;42:55-80 [11807164.001]
  • [Cites] Nat Med. 2002 Mar;8(3):282-8 [11875500.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):68-76 [11900253.001]
  • [Cites] Exp Cell Res. 2002 Jun 10;276(2):214-22 [12027451.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):541-8 [12050095.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2002;21(2):155-64 [12086402.001]
  • [Cites] Cancer Biol Ther. 2002 Jan-Feb;1(1):47-55 [12174820.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2171-81 [12612087.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5239-42 [14500353.001]
  • [Cites] Science. 2004 Feb 6;303(5659):844-8 [14704432.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Feb;4(1):29-42 [14965265.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):285-91 [15491287.001]
  • [Cites] Nutr Cancer. 2004;48(2):124-41 [15231447.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):45887-96 [15308639.001]
  • [Cites] J Natl Cancer Inst. 1986 Dec;77(6):1241-6 [3467115.001]
  • [Cites] Cancer Lett. 1987 Oct 30;37(2):147-51 [3677050.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7555-9 [1699228.001]
  • [Cites] Cancer Res. 1991 Sep 1;51(17):4528-34 [1831401.001]
  • [Cites] Cancer Res. 1993 Jun 1;53(11):2502-6 [8495412.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1464-72 [7882354.001]
  • (PMID = 19826045.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-25114; United States / NCI NIH HHS / CA / N01CN53300; United States / NCI NIH HHS / CA / R01 CA094962; United States / NCI NIH HHS / CA / R01 CA109247-05; United States / NCI NIH HHS / CA / R01 CA109247; United States / NCI NIH HHS / CA / CA094962-06; United States / NCI NIH HHS / CA / CA-94962; United States / NCI NIH HHS / CA / R01 CA094962-06; United States / NCI NIH HHS / CN / N01 CN053300; United States / NCI NIH HHS / CN / N01-CN-53300
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CP 31398; 0 / Carcinogens; 0 / Cdkn1a protein, rat; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclooxygenase Inhibitors; 0 / Membrane Proteins; 0 / Pyrazoles; 0 / Pyrimidines; 0 / Sulfonamides; 0 / Tumor Suppressor Protein p53; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Ptgs1 protein, rat; JCX84Q7J1L / Celecoxib; K7Q1JQR04M / Dinoprostone; MO0N1J0SEN / Azoxymethane
  • [Other-IDs] NLM/ NIHMS141657; NLM/ PMC2792897
  •  go-up   go-down


80. Mammen JM, James LE, Molloy M, Williams A, Wray CJ, Sussman JJ: The relationship of lymph node dissection and colon cancer survival in the Veterans Affairs Central Cancer Registry. Am J Surg; 2007 Sep;194(3):349-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of lymph node dissection and colon cancer survival in the Veterans Affairs Central Cancer Registry.
  • BACKGROUND: The extent of lymphadenectomy in colon cancer may impact potential to cure and accuracy of staging.
  • METHODS: The Veterans Affairs Central Cancer Registry database was queried for TNM stage I-III colon adenocarcinoma patients and yielded 5,823 individuals.
  • CONCLUSIONS: More extensive lymphadenectomy is associated with improved OS in stage II colon cancer patients.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Colonic Neoplasms / mortality. Colonic Neoplasms / surgery. Lymph Node Excision

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17693281.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Paraskeva PA, Ridgway PF, Olsen S, Isacke C, Peck DH, Darzi AW: A surgically induced hypoxic environment causes changes in the metastatic behaviour of tumours in vitro. Clin Exp Metastasis; 2006;23(2):149-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Components of the metastatic cascade were evaluated under in vitro laparoscopic conditions using a human colonic adenocarcinoma cell line (SW1222).
  • [MeSH-major] Adenocarcinoma / surgery. Cell Hypoxia. Colonic Neoplasms / surgery. Laparoscopy / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • Hazardous Substances Data Bank. HELIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol. 1996 Sep;271(3 Pt 1):C962-70 [8843727.001]
  • [Cites] Surg Laparosc Endosc. 1996 Apr;6(2):136-9 [8680636.001]
  • [Cites] Br J Surg. 1994 Jan;81(1):127-31 [8313088.001]
  • [Cites] Br J Surg. 1995 Mar;82(3):295-8 [7795990.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):699-703 [11597811.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Am J Pathol. 1993 Dec;143(6):1731-42 [8256859.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):680-7 [11821448.001]
  • [Cites] Surg Endosc. 2002 Mar;16(3):533-6 [11928043.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):941-3 [8640781.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):242-8 [9488523.001]
  • [Cites] J Immunol. 1979 Dec;123(6):2861-9 [315432.001]
  • [Cites] Dis Colon Rectum. 1983 Sep;26(9):571-2 [6223795.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Dis Colon Rectum. 1990 Jul;33(7):610-4 [2361432.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):689-90 [8916886.001]
  • [Cites] World J Surg. 2005 Aug;29(8):975-81 [15981046.001]
  • [Cites] Clin Exp Metastasis. 1997 Jan;15(1):19-25 [9009102.001]
  • [Cites] Surgery. 1994 Apr;115(4):424-8 [8165532.001]
  • [Cites] J Cell Biochem. 2000 Apr;78(1):47-61 [10797565.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] World J Surg. 1999 Oct;23(10):989-95; discussion 996-7 [10512937.001]
  • [Cites] Am J Surg. 1974 Jun;127(6):711-5 [4832139.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):285-9 [9226314.001]
  • [Cites] Oral Oncol. 1997 Nov;33(6):381-8 [9509120.001]
  • [Cites] Dis Colon Rectum. 1996 Feb;39(2):200-7 [8620788.001]
  • [Cites] Br J Cancer. 1998 Jun;77(11):1799-805 [9667649.001]
  • [Cites] Gynecol Oncol. 1993 Nov;51(2):141-9 [8276286.001]
  • [Cites] Cancer Res. 1990 Aug 15;50(16):5031-8 [2379169.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4509-15 [8813149.001]
  • (PMID = 16912913.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cadherins; 0 / Cell Adhesion Molecules; 0 / Extracellular Matrix Proteins; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 142M471B3J / Carbon Dioxide; 206GF3GB41 / Helium
  •  go-up   go-down


82. Chiang JM, Lin YS: Tumor spectrum of adult intussusception. J Surg Oncol; 2008 Nov 1;98(6):444-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of malignant colonic intussusception (63%) was significantly higher than that of enteric intussusception (20%), P = 0.001.
  • Primary colon adenocarcinoma (8 of 10 patients, 80%) and malignant lymphoma (2 of 10 patients, 20%) were the two most common underlying malignant lesions in the colon.
  • Whereas 80% of tumors associated with small bowel intussusception were benign, two-thirds of colonic intussusceptions had resulted from primary adenocarcinoma.
  • [MeSH-minor] Abdominal Pain / etiology. Adenocarcinoma / complications. Adenoma / complications. Adolescent. Adult. Aged. Aged, 80 and over. Cystadenocarcinoma, Mucinous / complications. Female. Humans. Lipoma / complications. Lymphoma, Large B-Cell, Diffuse / complications. Male. Middle Aged. Peutz-Jeghers Syndrome / complications. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [ErratumIn] J Surg Oncol. 2009 Jun 1;99(7):457
  • (PMID = 18668640.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


83. Suárez Grau JM, Suárez Artacho G, Ibáñez Delgado F, Alcántara Gijón F: [Jejuno-colonic fistula due to adenocarcinoma of the descending colon]. Cir Esp; 2007 Aug;82(2):135
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Jejuno-colonic fistula due to adenocarcinoma of the descending colon].
  • [Transliterated title] Fístula yeyunocólica por adenocarcinoma de colon descendente.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / pathology. Colon, Descending / pathology. Colonic Neoplasms / complications. Colonic Neoplasms / pathology. Fistula / etiology. Jejunal Diseases / etiology

  • MedlinePlus Health Information. consumer health - Fistulas.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785153.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


84. Rigo A, Gottardi M, Zamò A, Mauri P, Bonifacio M, Krampera M, Damiani E, Pizzolo G, Vinante F: Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Mol Cancer; 2010;9:273
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12.
  • Events triggered by CXCL12 may play a part, as CXCL12 drives the migration of both CXCR4-positive cancer cells and macrophages and may promote a molecular crosstalk between them.
  • RESULTS: Samples of HER1-positive colon cancer metastases in liver, a tissue with high expression of CXCL12, were analysed by immunohistochemistry.
  • Cancer cells stained positive for CXCR4, CXCL12, HER1, HER4 and GM-CSF.
  • Regulatory interactions among these proteins were validated via experiments in vitro involving crosstalk between human mononuclear phagocytes and the cell lines DLD-1 (human colon adenocarcinoma) and HeLa (human cervical carcinoma), which express the above-mentioned ligand/receptor repertoire.
  • CXCL12 induced mononuclear phagocytes to release HB-EGF, which activated HER1 and triggered anti-apoptotic and proliferative signals in cancer cells.
  • The cancer cells then proliferated and released GM-CSF, which in turn activated mononuclear phagocytes and induced them to release more HB-EGF.
  • CONCLUSIONS: CXCL12-driven stimulation of cancer cells and macrophages may elicit and reinforce a GM-CSF/HB-EGF paracrine loop, whereby macrophages contribute to cancer survival and expansion.
  • [MeSH-major] Chemokine CXCL12 / pharmacology. Colonic Neoplasms / metabolism. Granulocyte-Macrophage Colony-Stimulating Factor / metabolism. Intercellular Signaling Peptides and Proteins / metabolism. Macrophages / drug effects. Macrophages / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 1;94(9):3169-77 [10556204.001]
  • [Cites] N Engl J Med. 2010 Mar 11;362(10):875-85 [20220182.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Blood. 2002 Jan 1;99(1):52-60 [11756152.001]
  • [Cites] Biol Chem. 2003 Apr;384(4):575-88 [12751787.001]
  • [Cites] J Am Soc Mass Spectrom. 2003 Sep;14(9):1022-31 [12954170.001]
  • [Cites] Endocrinology. 2004 Sep;145(9):4232-43 [15192046.001]
  • [Cites] J Biol Chem. 1990 Nov 25;265(33):20241-6 [2173701.001]
  • [Cites] Nature. 1996 Feb 8;379(6565):557-60 [8596637.001]
  • [Cites] Int J Cancer. 1998 Sep 25;78(1):120-4 [9724103.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1715-23 [10029601.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):459-69 [15542430.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5278-83 [15958574.001]
  • [Cites] Blood. 2005 Jul 1;106(1):59-66 [15755902.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6493-7 [16061624.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1761-7 [16269611.001]
  • [Cites] Blood. 2006 Mar 1;107(5):2112-22 [16269622.001]
  • [Cites] Cancer Sci. 2006 May;97(5):341-7 [16630129.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3245-52 [16857992.001]
  • [Cites] Transplantation. 2007 Jan 15;83(1):71-6 [17220794.001]
  • [Cites] Acta Physiol (Oxf). 2007 May;190(1):9-19 [17428228.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1652-8 [17894551.001]
  • [Cites] J Exp Med. 2007 Nov 26;204(12):3037-47 [18025128.001]
  • [Cites] PLoS One. 2008;3(6):e2563 [18575622.001]
  • [Cites] J Neuroimmunol. 2008 Jul 31;198(1-2):9-13 [18533280.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):436-44 [18650914.001]
  • [Cites] J Biol Chem. 2008 Aug 22;283(34):23189-99 [18556651.001]
  • [Cites] Br J Cancer. 2008 Nov 4;99(9):1493-501 [18854833.001]
  • [Cites] J Clin Invest. 2008 Nov;118(11):3574-81 [18982164.001]
  • [Cites] Nature. 2009 Jan 1;457(7225):102-6 [19122641.001]
  • [Cites] Cancer Res. 2009 Dec 15;69(24):9281-90 [19934331.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1215-22 [10942360.001]
  • (PMID = 20946648.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokine CXCL12; 0 / HBEGF protein, human; 0 / Hbegf protein, mouse; 0 / Heparin-binding EGF-like Growth Factor; 0 / Intercellular Signaling Peptides and Proteins; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2964621
  •  go-up   go-down


85. Krstić M, Sovilj SP, Grgurić-Sipka S, Radosavljević Evans I, Borozan S, Santibanez JF, Kocić J: New ruthenium(II) complexes with N-alkylphenothiazines: synthesis, structure, in vivo activity as free radical scavengers and in vitro cytotoxicity. Eur J Med Chem; 2010 Sep;45(9):3669-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Finally, the cytotoxicity of complexes were assayed in four human carcinoma cell lines MCF-7, MDA-MB-453 (breast carcinoma), SW-480 (colon adenocarcinoma) and IM9 (myeloma multiple cells).

  • Hazardous Substances Data Bank. PHENOTHIAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20684856.001).
  • [ISSN] 1768-3254
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Free Radical Scavengers; 0 / Free Radicals; 0 / Organometallic Compounds; 0 / Phenothiazines; 7UI0TKC3U5 / Ruthenium; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase; GS9EX7QNU6 / phenothiazine
  •  go-up   go-down


86. Campanelli A, Prins C, Saurat JH: Chronic urticaria revealing a colonic adenocarcinoma. J Am Acad Dermatol; 2005 Jun;52(6):1105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic urticaria revealing a colonic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / complications. Colonic Neoplasms / complications. Urticaria / etiology

  • MedlinePlus Health Information. consumer health - Hives.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15928644.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


87. Bondi J, Bukholm G, Nesland JM, Bakka A, Bukholm IR: An increase in the number of adhesion proteins with altered expression is associated with an increased risk of cancer death for colon carcinoma patients. Int J Colorectal Dis; 2006 Apr;21(3):231-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An increase in the number of adhesion proteins with altered expression is associated with an increased risk of cancer death for colon carcinoma patients.
  • BACKGROUND AND AIMS: Reduced expression of components of the cell-cell adhesive cadherin-catenin complex has been related to the invasive phenotype in many malignancies, but the prognostic value of altered expression of its separate components varies in colon cancer.
  • Our objective was evaluation of the cadherin-catenin complex, considered as a functional unit, in colon carcinomas and its relationship to patient outcome.
  • PATIENTS AND METHODS: Tumours from 206 patients operated for colon adenocarcinoma were analysed using immunohistochemistry of E-cadherin, alpha, beta, and gamma-catenins, and p120ctn.
  • However, an increase in the number of proteins in the cadherin-catenin complex with altered expression was associated with an increased risk of cancer death (univariate P=0.002; multivariate P=0.007, HR 1.48, 95% CI 1.11-1.96).
  • CONCLUSIONS: An increase in the number of adhesion proteins with altered expression in the primary tumour is associated with increasingly impaired prognosis for patients operated for colon carcinoma.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Cadherins / analysis. Catenins / analysis. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9156-60 [1924379.001]
  • [Cites] J Cell Biol. 1995 Jul;130(2):461-71 [7542250.001]
  • [Cites] Science. 1991 Nov 29;254(5036):1359-61 [1962194.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1033-8 [10514384.001]
  • [Cites] Br J Cancer. 1999 Jun;80(7):1046-51 [10362114.001]
  • [Cites] Cancer Res. 1991 Dec 1;51(23 Pt 1):6328-37 [1933895.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):992-1005 [10931041.001]
  • [Cites] Mol Cell Biol. 1995 Sep;15(9):4819-24 [7651399.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):583-9 [12492499.001]
  • [Cites] Br J Surg. 1996 Apr;83(4):437-46 [8665230.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Cancer Res. 1993 Aug 1;53(15):3585-90 [8339265.001]
  • [Cites] Cell. 1991 May 31;65(5):849-57 [1904011.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3614-23 [10207085.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1690-5 [8453643.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):987-93 [7682767.001]
  • [Cites] Scand J Gastroenterol. 2000 Aug;35(8):839-46 [10994623.001]
  • [Cites] J Cell Biol. 2003 Nov 10;163(3):547-57 [14610057.001]
  • [Cites] Eur J Cancer. 1999 Jan;35(1):60-5 [10211089.001]
  • [Cites] J Surg Oncol. 1998 Jun;68(2):92-9 [9624037.001]
  • [Cites] J Cell Biol. 1985 Jan;100(1):327-32 [3880756.001]
  • [Cites] J Cell Sci. 2000 Apr;113 ( Pt 8):1319-34 [10725216.001]
  • [Cites] APMIS. 2004 Jan;112(1):49-56 [14961975.001]
  • [Cites] Cancer Lett. 1998 Oct 23;132(1-2):193-201 [10397474.001]
  • [Cites] Cancer Res. 1992 Oct 15;52(20):5770-4 [1394201.001]
  • [Cites] Bioessays. 1997 Oct;19(10):883-91 [9363682.001]
  • [Cites] Genes Dev. 2000 Jun 1;14(11):1319-31 [10837025.001]
  • [Cites] Curr Opin Cell Biol. 1998 Oct;10(5):629-39 [9818174.001]
  • [Cites] J Pathol. 1998 Jul;185(3):262-6 [9771479.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6282-7 [7954478.001]
  • [Cites] J Pathol. 1997 Jul;182(3):325-30 [9349236.001]
  • [Cites] J Cell Biol. 2003 Nov 10;163(3):525-34 [14610055.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3544-52 [8012979.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3241-5 [8324734.001]
  • (PMID = 15937692.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Catenins
  •  go-up   go-down


88. Ayachi SE, Borie F, Magous R, Sasaki K, le Nguyen D, Bali JP, Millat B, Jarrousse C: Contraction induced by glicentin on smooth muscle cells from the human colon is abolished by exendin (9-39). Neurogastroenterol Motil; 2005 Apr;17(2):302-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contraction induced by glicentin on smooth muscle cells from the human colon is abolished by exendin (9-39).
  • The effect of glicentin on the motor activity of colon has never been reported in humans.
  • Our aim was to determine if circular smooth muscle cells (SMC) from the human colon are target cells for glicentin or GLP-1, and if their motility is dependent upon these digestive hormones.
  • METHODS: Twenty-two resections were performed on patients operated for colon adenocarcinoma.
  • The SMC were isolated from colonic circular muscle layer and cell contraction was assessed.
  • CONCLUSIONS: The circular muscle from the human colon is a target tissue for glicentin and GLP-1.
  • [MeSH-major] Colon / drug effects. Glucagon / pharmacology. Muscle Contraction / drug effects. Muscle, Smooth / drug effects. Peptide Fragments / pharmacology. Protein Precursors / pharmacology

  • Hazardous Substances Data Bank. GLUCAGON .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15787950.001).
  • [ISSN] 1350-1925
  • [Journal-full-title] Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • [ISO-abbreviation] Neurogastroenterol. Motil.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / Protein Precursors; 133514-43-9 / exendin (9-39); 62340-29-8 / Glucagon-Like Peptides; 71567-77-6 / Glicentin; 89750-14-1 / Glucagon-Like Peptide 1; 9007-92-5 / Glucagon
  •  go-up   go-down


89. Godoy A, Ulloa V, Rodríguez F, Reinicke K, Yañez AJ, García Mde L, Medina RA, Carrasco M, Barberis S, Castro T, Martínez F, Koch X, Vera JC, Poblete MT, Figueroa CD, Peruzzo B, Pérez F, Nualart F: Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol; 2006 Jun;207(3):614-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues.
  • GLUT2 was detected in 31% of the samples, being mainly expressed in breast, colon, and liver carcinoma.
  • GLUT5 was detected in 27% of breast and colon adenocarcinoma, liver carcinoma, lymphomas, and testis seminoma samples.
  • In situ RT-PCR and ultrastructural immunohistochemistry confirmed GLUT5 expression in breast cancer.
  • GLUT6 and 9 are not clearly over-expressed in human cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16523487.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transport Proteins, Facilitative
  •  go-up   go-down


90. West NP, Morris EJ, Rotimi O, Cairns A, Finan PJ, Quirke P: Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study. Lancet Oncol; 2008 Sep;9(9):857-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study.
  • BACKGROUND: High-quality rectal cancer surgery is known to improve patient outcome.
  • We aimed to assess the quality of colon cancer surgery by studying the extent of variation in the plane of surgical resection, the amount of tissue removed, and its association with survival.
  • METHODS: All resections for primary colon adenocarcinoma done at Leeds General Infirmary (Leeds, UK) between Jan 1, 1997, and June 30, 2002, were identified.
  • INTERPRETATION: As previously shown in the rectum, we have now shown there is marked variability in the plane of surgery achieved in colon cancer.
  • If confirmed by clinical trial data, such as from the ongoing National Cancer Research Institute Fluoropyrimidine, Oxaliplatin and Targeted Receptor pre-Operative Therapy for colon cancer (FOxTROT) trial of neoadjuvant chemotherapy in advanced resectable colon cancer, improvement of the plane of dissection might be a new cost-effective method of decreasing morbidity and mortality in patients with colon cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / standards. Colonic Neoplasms / surgery. Neoplasm Recurrence, Local / prevention & control. Quality of Health Care

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2008 Sep;9(9):815-7 [18760238.001]
  • (PMID = 18667357.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 9805; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


91. Kulbacka J, Chwilkowska A, Bar J, Pola A, Banas T, Gamian A, Saczko J: Oxidative alterations induced in vitro by the photodynamic reaction in doxorubicin-sensitive (LoVo) and -resistant (LoVoDX) colon adenocarcinoma cells. Exp Biol Med (Maywood); 2010 Jan;235(1):98-110
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxidative alterations induced in vitro by the photodynamic reaction in doxorubicin-sensitive (LoVo) and -resistant (LoVoDX) colon adenocarcinoma cells.
  • This study deals with photodynamic therapy with Photofrin (Ph) on colon cancer cell lines (doxorubicin-sensitive and -resistant).
  • Moreover, the expressions of glutathione S-transferase (GST)-pi, a marker protein for photochemical toxicity, and secretory phospholipase A(2), a prognostic and diagnostic marker for colon cancers, were determined.
  • Our study presents that PDR caused oxidative alterations in both examined colon adenocarcinoma cell lines.
  • [MeSH-major] Adenocarcinoma / drug therapy. Colonic Neoplasms / drug therapy. Hematoporphyrin Photoradiation

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20404024.001).
  • [ISSN] 1535-3699
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Proteins; 0 / Sulfhydryl Compounds; 0 / Thiobarbituric Acid Reactive Substances; 80168379AG / Doxorubicin; 97067-70-4 / Dihematoporphyrin Ether; EC 1.15.1.- / superoxide dismutase 1; EC 1.15.1.1 / Superoxide Dismutase; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 3.1.1.4 / Group II Phospholipases A2
  •  go-up   go-down


92. Blanchette J, Peppas NA: Oral chemotherapeutic delivery: design and cellular response. Ann Biomed Eng; 2005 Feb;33(2):142-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of carriers to deliver a variety of cancer therapeutics orally would represent a significant advance in the treatment of this disease.
  • The potential cytotoxicity of bleomycin on the small intestine was investigated with the use of Caco-2 cells (human colon adenocarcinoma).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771268.001).
  • [ISSN] 0090-6964
  • [Journal-full-title] Annals of biomedical engineering
  • [ISO-abbreviation] Ann Biomed Eng
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / EB-000246
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Coated Materials, Biocompatible; 0 / Delayed-Action Preparations; 11056-06-7 / Bleomycin; 30IQX730WE / Polyethylene Glycols; 9011-14-7 / Polymethyl Methacrylate
  •  go-up   go-down


93. Doleman JF, Eady JJ, Elliott RM, Foxall RJ, Seers J, Johnson IT, Lund EK: Identification of the Eph receptor pathway as a novel target for eicosapentaenoic acid (EPA) modification of gene expression in human colon adenocarcinoma cells (HT-29). Nutr Metab (Lond); 2010;7:56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the Eph receptor pathway as a novel target for eicosapentaenoic acid (EPA) modification of gene expression in human colon adenocarcinoma cells (HT-29).
  • METHODS: We used microarrays to assess the effects on gene expression in HT29 colon adenocarcinoma cells of exposure to the n-3 fatty acid eicosapentaenoic acid (EPA).
  • CONCLUSIONS: Eph receptor mediated signaling is an entirely novel signaling pathway through which EPA may promote a wide range of health benefits, in particular in relation to reduction of colorectal cancer progression.


94. Deng H, Ravikumar TS, Yang WL: Bone morphogenetic protein-4 inhibits heat-induced apoptosis by modulating MAPK pathways in human colon cancer HCT116 cells. Cancer Lett; 2007 Oct 28;256(2):207-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone morphogenetic protein-4 inhibits heat-induced apoptosis by modulating MAPK pathways in human colon cancer HCT116 cells.
  • Cancer thermotherapy and radiofrequency ablation (RFA) have been adopted as modalities for treating various kinds of cancer.
  • We have previously demonstrated that bone morphogenetic protein-4 (BMP-4) is up-regulated in colonic adenocarcinoma.
  • Here, we investigated whether an increase of BMP-4 expression changes cellular response to heat treatment in human colon cancer HCT116 cells.
  • These results indicate that BMP-4 can protect colon cancer cells from heat-induced apoptosis through enhancing the activation of ERK as well as inhibiting the activation of JNK.
  • [MeSH-major] Adenocarcinoma / therapy. Apoptosis. Bone Morphogenetic Proteins / metabolism. Colonic Neoplasms / therapy. Extracellular Signal-Regulated MAP Kinases / metabolism. Hyperthermia, Induced. JNK Mitogen-Activated Protein Kinases / metabolism. Signal Transduction

  • Genetic Alliance. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640799.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / BAX protein, human; 0 / BMP4 protein, human; 0 / Bone Morphogenetic Protein 4; 0 / Bone Morphogenetic Proteins; 0 / Carrier Proteins; 0 / Flavonoids; 0 / HSP27 Heat-Shock Proteins; 0 / HSP70 Heat-Shock Proteins; 0 / HSP90 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Heat-Shock Proteins; 0 / Neoplasm Proteins; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 148294-77-3 / noggin protein; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  •  go-up   go-down


95. Bun SS, Elias R, Baghdikian B, Ciccolini J, Ollivier E, Balansard G: Alpha-hederin potentiates 5-FU antitumor activity in human colon adenocarcinoma cells. Phytother Res; 2008 Oct;22(10):1299-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-hederin potentiates 5-FU antitumor activity in human colon adenocarcinoma cells.
  • The aim of this study was to investigate the ability of alpha-hederin to improve the efficacy of widely prescribed 5-fluorouracil (5-FU) in a human colon adenocarcinoma model.
  • The data indicate therefore that it is possible to optimize colorectal cancer cell sensitivity to 5-FU with alpha-hederin.

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 John Wiley & Sons, Ltd.
  • (PMID = 18546204.001).
  • [ISSN] 1099-1573
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Saponins; 27013-91-8 / alpha-hederin; 6SMK8R7TGJ / Oleanolic Acid; U3P01618RT / Fluorouracil
  •  go-up   go-down


96. Zheng Y, Yang XW: [Absorption of triterpenoid compounds from Indian bread (Poria cocos) across human intestinal epithelial (Caco-2) cells in vitro]. Zhongguo Zhong Yao Za Zhi; 2008 Jul;33(13):1596-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: By using Caco-2 (the human colonic adenocarcinoma cell lines) cells monolayer as an intestinal epithelial cell model, the permeability of EDHTA, PPAC and HPPA were studied from apical side (AP side) to basolateral side (BL side) or from BL side to AP side.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837324.001).
  • [ISSN] 1001-5302
  • [Journal-full-title] Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
  • [ISO-abbreviation] Zhongguo Zhong Yao Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Triterpenes
  •  go-up   go-down


97. Shnyder SD, Cooper PA, Millington NJ, Pettit GR, Bibby MC: Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models. Int J Oncol; 2007 Aug;31(2):353-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models.
  • Herein the mechanism of action and efficacy of a synthetic analogue, auristatin PYE, was investigated in 2 human colon adenocarcinoma models, DLD-1 and COLO 205.
  • These data suggest that auristatin PYE has good potential as an anti-cancer agent.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Colonic Neoplasms / drug therapy. Depsipeptides / chemistry. Depsipeptides / pharmacology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611692.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA90441-03-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Depsipeptides; 0 / auristatin PYE; 110417-88-4 / dolastatin 10
  •  go-up   go-down


98. Su YC, Chuang KH, Wang YM, Cheng CM, Lin SR, Wang JY, Hwang JJ, Chen BM, Chen KC, Roffler S, Cheng TL: Gene expression imaging by enzymatic catalysis of a fluorescent probe via membrane-anchored beta-glucuronidase. Gene Ther; 2007 Apr;14(7):565-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A functional beta-glucuronidase (betaG) was stably expressed on the surface of murine CT26 colon adenocarcinoma cells where it selectively hydrolyzed the cell-impermeable FDGlcU probe.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17235292.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fluoresceins; 0 / Fluorescent Dyes; 74804-84-5 / fluorescein glucuronide; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


99. Verbeke H, De Hertogh G, Li S, Vandercappellen J, Noppen S, Schutyser E, El-Asrar AA, Opdenakker G, Van Damme J, Geboes K, Struyf S: Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer. Hum Pathol; 2010 Jul;41(7):990-1001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer.
  • In this study, the regulated expression of angiogenic (stromal cell-derived factor [SDF]-1/CXCL12 and interleukin [IL]-8/CXCL8) and angiostatic (platelet factor [PF]-4var/CXCL4L1 and inducible protein [IP-10]/CXCL10) chemokines was examined in human colorectal and esophageal cancer.
  • In HCT 116 and HCT-8 colorectal adenocarcinoma cells, the production of IL-8 immunoreactivity was up-regulated by IL-1beta, tumor necrosis factor (TNF)-alpha, the toll-like receptor (TLR) ligands double-stranded RNA and peptidoglycan and phorbol ester.
  • In addition, IL-8 from HT-29 colorectal adenocarcinoma cells was molecularly identified as intact chemokine, as well as NH(2)-terminally truncated, more active IL-8(6-77).
  • The presence of PF-4var, SDF-1, and vascular endothelial growth factor (VEGF) was evidenced by immunohistochemistry in surgical samples from 51 patients operated on for colon adenocarcinoma (AC), esophageal AC, or esophageal squamous cell carcinoma (SCC).
  • PF-4var was strongly detected in colorectal cancer, whereas its expression in esophageal cancer was rather weak.
  • Staining for SDF-1 was almost negative in esophageal SCC, whereas a more intense and frequent staining was observed in AC of the esophagus and colon.
  • Staining for VEGF was moderately to strongly positive in all 3 types of cancer, although less prominent in esophageal AC.
  • [MeSH-minor] Adenocarcinoma / blood supply. Adenocarcinoma / metabolism. Aged. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / metabolism. Cell Line, Tumor. Colon / metabolism. Enzyme-Linked Immunosorbent Assay. Esophagus / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mucous Membrane / metabolism. Neovascularization, Pathologic / metabolism. Reverse Transcriptase Polymerase Chain Reaction


100. Dillman RO, Aaron K, Heinemann FS, McClure SE: Identification of 12 or more lymph nodes in resected colon cancer specimens as an indicator of quality performance. Cancer; 2009 May 1;115(9):1840-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of 12 or more lymph nodes in resected colon cancer specimens as an indicator of quality performance.
  • BACKGROUND: : Identification of > or =12 lymph nodes in resected colon cancer specimens has been endorsed as a quality indicator.
  • METHODS: : The Hoag Hospital cancer registry was used to identify patients diagnosed with colon cancer.
  • The proportion of colon cancer specimens for which > or =12 lymph nodes were identified was determined by anatomic location, stage of disease, patient age, and operating surgeon.
  • RESULTS: : Pathology procedural changes in 1998 were associated with an increase in the average number of lymph nodes identified from 8.0 to 14.5 (P < .0001); therefore, analysis was limited to 574 patients who underwent surgical resection of colon adenocarcinoma during 1998 to 2005.
  • Cancer 2009. (c) 2009 American Cancer Society.
  • [MeSH-major] Colonic Neoplasms / pathology. Lymph Nodes / pathology. Lymphatic Metastasis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208427.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement